

**CURRICULUM VITA****Michael B. Nichol, Ph.D.****PERSONAL INFORMATION**

Business Address	University of Southern California Sol Price School of Public Policy Ralph and Goldy Lewis Hall 326 Los Angeles, California 90089
Business Telephone	(213) 740-2355 (voice)
Electronic Mail	mnichol@usc.edu

**EDUCATION**

1987	- University of Southern California, Ph.D., Public Administration <i>Dissertation:</i> The effects of centralization and board membership reform on occupational licensing policies.
1983	- University of Oregon, M.S., Public Affairs <i>Thesis:</i> Application of a cost-benefit methodology to health facility capital expenditures.
1974	- University of Tulsa, B.A., Political Science

**PROFESSIONAL EXPERIENCE**

2015-present	Professor of Public Policy Vice Dean for Faculty Affairs Interim Chair, Department of Health Policy and Management, University of Southern California, Sol Price School of Public Policy, Los Angeles, California
2009-present	Professor of Public Policy and Pharmacy Director, Graduate Health Programs, University of Southern California, Sol Price School of Public Policy, Los Angeles, California
2007-2015	Professor of Pharmaceutical Economics and Policy, University of Southern California, School of Pharmacy, Los Angeles, California
2007-2009	Professor, University of Southern California, School of Policy, Planning, and Development, Los Angeles, California
2007-present	Professor, Program in Policy and Services Research, Andrus Gerontology Center, University of Southern California

- 2007-2009      QSAD Centurion Professor of Pharmaceutical Economics and Policy, University of Southern California, School of Pharmacy, Los Angeles, California
- 1999-2007      QSAD Centurion Associate Professor of Pharmaceutical Economics and Policy, University of Southern California, School of Pharmacy, Los Angeles, California
- 1998-2006      Chair, Department of Pharmaceutical Economics and Policy, University of Southern California, School of Pharmacy, Los Angeles, California
- 1993-2007      Associate Professor of Pharmaceutical Economics and Policy, University of Southern California, School of Pharmacy, Los Angeles, California
- 1995-2007      Associate Professor, University of Southern California, School of Policy, Planning, and Development, Los Angeles, California
- 1993-2007      Associate Professor, Program in Policy and Services Research, Andrus Gerontology Center, University of Southern California
- 1987-1993-      Assistant Professor of Pharmaceutical Economics and Policy, University of Southern California, School of Pharmacy, Los Angeles, California
- 1992-1993-      Assistant Professor, Program in Policy and Services Research, Andrus Gerontology Center, University of Southern California
- 1988-present - Senior Research Associate, Program in Policy and Services Research, Gerontology Research Institute, Andrus Gerontology Center, University of Southern California
- 1986            - Lecturer (Introduction to Policy Analysis, undergraduate), University of Southern California, School of Public Administration
- 1984-present - Consultant, various organizations
- 1984-1987      - Research Assistant, University of Southern California, School of Public Administration
- 1984            - Instructor (Health Program Planning and Evaluation, graduate seminar), University of Oregon, School of Community and School Health
- 1983-1984      - Executive Director, Western Oregon Health Systems Agency, Eugene, Oregon
- 1981-1983      - Planning and Review Manager, Western Oregon Health Systems Agency
- 1979-1981      - Assistant Director for Planning, Western Oregon Health Systems Agency
- 1977-1979      - Health Planning Associate, Western Oregon Health Systems Agency
- 1974-1977      - Health Planner, Oregon State Health Planning and Development Agency, Salem, Oregon

**HONORS**

- 2012 Robert Biller Outstanding Faculty Award, Price School
- 2011 Ideas Empowered Entrepreneur Team, Stevens Institute (USC, one of five teams funded)
- 2011 Best Poster finalist, 16<sup>th</sup> Annual Meeting of the International Society of Pharmacoeconomics and Outcomes Research (with Wu, Huang, Denham, Hsu, Frencher, Loo, Jacobsen)
- 2011 Best Student Podium Research Presentation, 16<sup>th</sup> Annual Meeting of the International Society of Pharmacoeconomics and Outcomes Research (awarded to Jae Jin An, with MB Nichol)
- 2010 Issues Panel Co-Chair, 15<sup>th</sup> Annual Meeting of the International Society of Pharmacoeconomics and Outcomes Research
- 2009 Best Student Poster Presentation Award, 14<sup>th</sup> Annual Meeting of the International Society of Pharmacoeconomics and Outcomes Research (awarded to AA Kawatkar, with MB Nichol)
- 2008 President, USC Academic Senate
- 2007 Health Systems Research Study Section, Agency for Healthcare Research and Quality (AHRQ)
- 2004 Mentor, PhRMA Dissertation Award (J. Epstein, student)
- 2004 Distinguished Faculty Service Award, Academic Senate
- 2004 Best New Investigator Poster Presentation Award, 9<sup>th</sup> Annual Meeting of the International Society of Pharmacoeconomics and Outcomes Research (awarded to C Quach, with MB Nichol, L Chen, B. Patel, P Thiebaud, and D. Berenbeim)
- 2000 North American Menopause Society National Conference, best poster
- 1999 Best presentation poster, 2<sup>nd</sup> European Conference of the International Society for Pharmacoeconomics and Outcomes Research, Edinburgh, Scotland, November 1999
- 1999 QSAD Centurion Professorship, School of Pharmacy
- 1993 Drug Therapy Research Award, American Society of Hospital Pharmacists Research and Education Foundation (with JA Zeisler, JD McCarthy, and WA Richelieu)
- 1992 Burlington Resources Foundation Faculty Achievement Award for Outstanding Scholar
- 1992 Phi Lambda Sigma, University of Southern California Chapter (Pharmacy Leadership Society)
- 1992 The Searle Fellowship in Pharmacy, Faculty Mentor Award (Second Place)
- 1991 The Searle Fellowship in Pharmacy, Faculty Mentor Award (Third Place)
- 1990 Mentor, Rorer Pharmaceuticals Managed Care Demonstration Project
- 1990 The Searle Fellowship in Pharmacy, Faculty Mentor Award (Third Place)
- 1984-1986 Scapa Praetors Student Fellowship recipient
- 1983-1987 Pi Alpha Alpha (Public Administration Honor Society)

**GRANTS**

**Nichol MB.** Hemophilia User Group (HUGS) : Fifth Year Followup study, 4/14-1/16, multiple sponsors, \$250,000 (direct)

**Nichol MB.** Economic Evaluation of QuantiFERON®-CMV Test (\$75,000 direct costs) 2/14-8/15, Qiagen, \$75,000 (direct)

**Nichol MB.** Hemophilia User Group (HUGS) VI: Adherence, 12/13-12/16, Biogen Idec, \$550,000 (direct, approximate)

**Nichol MB** and Wilber K. Evaluating the cost-effectiveness of the Elder Abuse Forensic Center Model, 1/12-12/13, Department of Justice, \$484,448 (direct)

**Nichol MB.** Hemophilia User Group (HUGS) Va study, 1/08-12/12, multiple sponsors, \$290,000 (direct, approximate)

**Nichol MB.** Hemophilia User Group (HUGS) Vb study, 1/10-12/15, multiple sponsors, \$325,000 (direct, approximate)

**Nichol MB, Wu J.** The Impact of adherence with 5-ASA therapy on health care utilization and costs among patients with ulcerative colitis. Shire Development LLC, 10/11-03/14, \$177,000 (direct)

**Nichol MB, Wu J.** Study of adherence and persistence with 5-ASA therapy for ulcerative colitis in the U.S. Shire Development LLC, 6/11-12/11, \$30,000 (direct)

Atkins S, Enguidanos S, **Nichol MB.** E-Consult pilot project evaluation, 1/11-4/11, CTSI pilot project competition, \$30,000 (direct)

**Nichol MB.** Medical expenditures associated with transition from diverticulosis to diverticulitis. Kaiser Permanente, 7/10-10/10, \$30,000 (direct)

**Nichol MB.** Manuscript development: A budget impact model to evaluate medication persistence and associated health costs in diverticulosis and diverticulitis. Shire, 4/10-4/11, \$24,500 (direct)

**Nichol MB.** Patterns and predictors of transitions in adult attention deficit hyperactivity disorder. Shire, 3/09-6/11, \$35,000 (direct)

Wilber K and **Nichol MB** (co-investigator). An assessment of the Protective Services Senior Center, National Institute of Justice, 2/10-2/13, \$15,000 (direct Nichol)

- Nichol MB.** A Review of Intervention Programs to Improve Medication Adherence in Gastrointestinal Disease and other Chronic Conditions. Shire, 7/09-7/10, \$30,750 (direct)
- Nichol MB.** Health Care Utilization and Quality of Life in Diverticulosis. Shire, 7/09-9/10, \$118,000 (direct)
- Nichol MB.** Cost-Effectiveness Analysis of a new Laboratory Tool for Screening Prostate Cancer. Kaiser Permanente, 7/09-7/10, \$130,000 (direct)
- Nichol MB, Chao S, Parry T.** USC-IBI Pilot Project: A Simulation Model for Employer Health Benefit Decision Making, Phase II, Benefit Design Institute, 7/1/08-7/31/09, \$175,000 (direct)
- Nichol MB, Gwadry-Sridhar F, Foody J, Knight T.** Healthy Employee Adherence Research Trial (HEART). Pfizer, 3/07-12/09, \$245,000 (direct)
- Nichol MB, Gwadry-Sridhar F, Knight T, Dow T.** The Value of Medicine in a Low-Income Population. Glaxo Smith-Kline, 10/1/06-6/31/07, \$87,100 (direct)
- Nichol MB, Chao S, Parry T.** USC-IBI Pilot Project: A Simulation Model for Employer Health Benefit Decision Making, Benefit Design Institute, 7/1/06-7/31/07, \$199,990 (direct)
- Nichol MB, Gwadry-Sridhar F, Knight T, Dow T.** Evaluating Medication Compliance in a CareMark Managed Care Population. Glaxo Smith-Kline, 6/1/06-2/28/07, \$116,000 (direct)
- Nichol MB, Knight T, Dow T.** A Retrospective Study to Evaluate the Impact of Medicare's Part D Prescription Drug Benefit on Medicaid-Medicare Dually Eligible Beneficiaries, 6/1/06-3/31/07, \$60,000 (direct)
- Nichol MB, Knight T, Dow T.** Predictive Modeling in a California Medicaid Population with Diabetes: Model Development and Validation. Novo Nordisk, 5/1/06-10/30/06, \$42,500 (direct)
- Nichol MB, Parry T, Knight T, Dow T.** The Impact of a Consumer-Directed Health Plan (CDHP) on Patient Outcomes: A Case Study in a Wells Fargo Diabetes Population. Pfizer, 6/1/05-1/1/07, \$60,000 (direct)
- Nichol MB, Knight T.** Clinically Meaningful Change on Functional Assessment of Cancer Therapy: Patients with Metastatic Hormone Refractory Prostate Cancer, Abbott Laboratories, 12/31/05-3/31/06, \$9,500 (direct)

- Nichol MB**, Knight T, Dow T. Evaluating Medication Treatment Patterns in a Benign Prostatic Hyperplasia (BPH) Medicaid Population. Allergan, 8/1/05-3/31/06, \$49,500 (direct)
- Nichol MB**, Benner J, Knight T, Dow T. Clinical and Economic Outcomes of Nonadherence to Antihypertensive and Lipid-Lowering Drugs in High-Risk Primary Prevention Patients. Pfizer, 6/1/05-5/31/06, \$115,000 (direct)
- Nichol MB**, Knight T, Dow T. Evaluation of Pitney Bowes Predictive Modeling Approach. Pfizer, 6/1/05-12/1/06, \$84,000 (direct)
- Nichol MB**, Epstein J, Knight T, Dow T. Evaluating the Cost of Care for Various Stages of Oropharyngeal Cancer in the California Medicaid Population. Zila, 5/1/05-8/31/05, \$30,834 (direct)
- Nichol MB**, Knight T, Dow T. Cost-Effectiveness of Botox in Benign Prostatic Hyperplasia. Allergan, 5/1/05-4/30/06, \$59,580 (direct)
- Nichol MB**, Knight T, Dow T. Predictive Modeling in a Patient Population at Risk for Cardiovascular Disease. Novartis, 11/1/04-12/17/04, \$33,347 (direct)
- Nichol MB** and McCombs JS. The Medi-Cal/USC project. Pfizer, 7/1/03-12/31/07, \$52,000 (direct)
- Nichol MB**, Knight T, Dow T. Quality of anticoagulation control and cost of monitoring warfarin therapy within an anticoagulation clinic. Astra-Zeneca, 12/1/03-12/1/04, \$40,127 (direct)
- Nichol MB**. Current patterns of care and treatment costs associated with venous thromboembolic disease (DVT). Astra-Zeneca, 12/1/03-12/1/04, \$15,109 (direct)
- Nichol MB** and McCombs JS. The Medi-Cal/USC project: Statins and Triptans. Pfizer, 7/1/03-6/31/04, \$120,000 (direct)
- Nichol MB** and Globe DS. Evaluating the AMCP dossier submission process. Pfizer, 10/1/03-9/1/04, \$104,400 (direct)
- Nichol MB**. A retrospective evaluation of spasticity in stroke patients in a Medi-Cal population. Allergan, 10/1/03-9/1/04, \$51,500 (direct)
- Nichol MB**, Knight T, Shi S. Clinical cohort definitions for congestive heart failure, Los Angeles County, 6/1/01-12/1/01, \$31,650 (direct)
- Nichol MB** and Harada ASM. Beta-blocker therapy in chronic open-angle glaucoma, Allergan, 6/1/99-12/1/99, \$49,875 (direct)

**Nichol MB.** PacifiCare Quality Improvement Initiatives: Economic analysis of the return on investment, PacifiCare, 5/1/99-10/31/99, \$129,375 (direct)

**Nichol MB** and McCombs JS. Utilization of antipsychotic medications in the treatment of schizophrenia in a managed care population, Phase I: Retrospective analysis of pharmacy claims and health care services encounter data, Janssen Pharmaceuticals, 1/1/99-10/1/99, \$66,425 (direct)

**Nichol MB.** A study assessing patient evaluation and cost-minimization of an over-the-counter antimigraine medication in a managed care population, Bristol-Myers Squibb, 10/1/98-10/1/99, \$178,375 (direct)

**Nichol MB.** Quality Initiative in depression at Prescription Solutions, Prescription Solutions, 5/1/98-12/1/98, \$39,925 (direct)

**Nichol MB** and McCombs JS. Utilization of antidepressants in a managed care population, Eli Lilly and Co., 12/1/98-10-15-99, \$62,875 (direct)

**Nichol MB.** Costs associated with discontinuation of antihypertensive therapy, Hoechst Marion Roussel, 1/1/98-12/31/98, \$52,992. (direct)

McCombs JS, **Nichol MB** and Stimmel G. The role of serotonin-specific re-uptake inhibitor (SSRI) antidepressants for the treatment of depressed patients in the California Medicaid (Medi-Cal) population. Eli Lilly and Co. \$71,291.

McCombs JS, **Nichol MB** and Stimmel G. The cost of treating bipolar disorder in the California Medicaid (Medi-Cal) population. Eli Lilly and Co. \$65,188.

McCombs JS, **Nichol MB** and Stimmel G. The cost of treating schizophrenia in the Medicaid programs of selected states. Sub-contractor to Muse and Associates on a grant from Eli Lilly and Co. \$33,675.

McCombs JS and **Nichol MB.** Cost of treating Parkinson's Disease in the California Medicaid population, Pharmacia and Upjohn, 12/1/97-4/30/98, \$63,000.

**Nichol MB.** Effects of a therapeutic interchange program on patient outcomes, Astra Merck, 9/1/97-3/31/98.

**Nichol MB.** Development of a Central System for MUE/DUE/CAs Collection and Analysis, Astra Merck, 1/1/97-6/30/00, \$35,340.

**Nichol MB.** Quality of care for breast cancer patients undergoing adjuvant treatment, Amgen, 7/1/96-3/31/99, \$157,270.

**Nichol MB.** Treatment for GERD in a managed care population, Astra Merck Group, 10/1/95-2/15/97.

**Nichol MB.** Describing psoriasis-related health care utilization: A two-part study (Phase I), Allergan-Herbert, 9/1/95-3/1/96.

McCombs JS and **Nichol MB.** The role of SSRI antidepressants for treating depressed patients in the California Medicaid program, Eli Lilly, 9/1/95-2/1/96.

**Nichol MB.** Costs and practice patterns associated with treating GERD and DU in a Medi-Cal population: Phase II, Astra Merck Group, 3/1/95-11/1/95.

**Nichol MB.** Costs and practice patterns associated with treating GERD and DU in a Medi-Cal population: Phase I, Astra Merck Group, 9/1/94-3/1/95.

**Nichol MB.** Economic issues associated with needle-stick injuries in home infusion settings: Phase I, Home Infusion Therapy Coalition of California, 6/1/94-12/31/94.

**Nichol MB.** ASCP Pharmacoeconomics fellowship in geriatric long-term care (Karen Bailey), (funded by Bristol-Myers Squibb), 8/1/94-8/1/96.

**Nichol MB.** Impacts of pharmacist interventions in a managed care setting, Astra Merck, 12/1/93-5/1/94.

**Nichol MB.** A retrospective cost comparison of second generation diabetic agents, Upjohn, 10/1/93-3/31/94.

McCombs JS, Hay JW, **Nichol MB**, Johnson KA, Hill-Besinque K. Effect of different pharmacy services on patient outcomes, resource utilization, and medication compliance, Kaiser-Permanente Medical Care Program, Southern California Region, 8/92-7/95.

Williams BR, Lipson L, Lowe B, **Nichol MB**, McCombs JS. The impact of clinical pharmacist services on drug use in residential care facilities for the elderly, John A. Hartford Foundation, 7/89-1/92.

Sciar DA, McCombs JS and **Nichol MB.** Cost-effectiveness of transdermal delivery systems for antihypertensive medication, Beohringer-Ingelheim, 7/89-6/90.

Sciar DA, McCombs JS and **Nichol MB.** Development of econometric acuity matrices for post-marketing surveillance, Upjohn Company, 3/89-2/90.

**Nichol MB** and McCombs JS. Over-the-counter drug counseling project, Bergen-Brunswig Drug Company, 11/88-11/89.



McCombs JS, **Nichol MB**, Sclar DA and Stimmel GL. The use and cost of services for Medi-Cal patients with generalized anxiety disorder and neurotic depression, Bristol-Myers, Inc., 9/89-11/89.

McCombs JS and **Nichol MB**. The use and cost of services for patients with major depressive disorders, Eli Lilly, 8/89-11/89.

## **EDITORIAL**

- Reviewer, Arthritis and Rheumatism, Journal of General Internal Medicine; Medical Decision Making; Disease Management and Health Outcomes; Value in Health; Journal of Quality of Life Research; Health Affairs; Journal of Clinical Epidemiology; Expert Review of Pharmacoeconomics and Outcomes Research; Alimentary Pharmacology & Therapeutics; Clinical Therapeutics; JAMA; Pharmaceutical Research; Pharmacoeconomics; Medical Care; Van Nostrand Reinhold; Annals of Pharmacotherapy; Journal of Pharmacy Technology; Journal of Social and Administrative Pharmacy

**BIBLIOGRAPHY****Michael B. Nichol****ARTICLES IN REFEREED PUBLICATIONS**

91. Curtis R, Baker J, Riske B, Ullman M, Niu X, Norton K, Lou M, **Nichol MB**. Young adults with hemophilia in the U.S.: Demographics, comorbidities, and health status. *American Journal of Hematology*, 90(S2): S11-16, 2015.
90. Navarro AE, Wysong J, Deliema M, Schwartz E, **Nichol MB**, Wilber K. Inside the Black Box: The Case Review Process of an Elder Abuse Forensic Center. *The Gerontologist*, 2015 Aug 6. pii: gnv052. [Epub ahead of print]
89. Yeomans K, Allen-Ramey F, Smith N, Kim H, Lockey RF, **Nichol MB**. Administration and burden of subcutaneous immunotherapy for allergic rhinitis in Canadian and US clinical practice. *Journal of Managed Care Specialty Pharmacy*, 21(11):982-991, 2015
88. Zhou Z, Koerper MA, Johnson KA, Riske B, Baker JR, Ullman M, Curtis RG, Poon JL, **Nichol MB**. Burden of illness: Direct and indirect costs among persons with hemophilia A in the United States. *Journal of Medical Economics*, 2015; 18:457-65
87. Niu X, Poon JL, Riske B, Zhou ZY, Ullman M, Lou M, Baker J, Koerper M, Curtis R, **Nichol MB**. Physical activity and health outcomes in persons with hemophilia B. *Hemophilia*, 20(6): 814-21, 2014.
86. Poon JL, Doctor JN, **Nichol MB**. Longitudinal changes in health-related quality of life for chronic diseases: An example in hemophilia A. *Journal of General Internal Medicine*, 29(Supplement 3): S760-6, 2014.
85. Kawatkar A, Knight TK, Moss RA, Sikirica V, Chu LH, Hodgkins P, Erder MH, **Nichol MB**. Impact of mental health comorbidities on health care utilization and expenditure in a large US managed care adult population with ADHD, *Value in Health* 17(6): 661-8, 2014.
84. Knight TK, Kawatkar A, Hodgkins P, Moss RA, Chu LH, Sikirica V, Erder MH, **Nichol MB**. Prevalence and incidence of adult attention deficit/hyperactivity disorder in a large managed care population, *Current Medical Research and Opinion* 30(7): 1291-9, 2014.
83. Yen L, Knight TK, Sharma G, **Nichol MB**, McDermott JD, Hodgkins P. Adherence to 5-ASA therapy in ulcerative colitis: Budget impact analysis. *American Journal of Pharmacy Benefits*, 5(1):e15-e23, 2013
82. An JX, **Nichol MB**. Multiple medication adherence and its effect on clinical outcomes among patients with Type 2 diabetes and comorbid hypertension, *Medical Care*, 51(10): 879-887, 2013.

81. Wallner LP, Frencher SK, Hsu JW, Chao CR, **Nichol MB**, Loo RK, Jacobsen SJ. Changes in serum prostate-specific antigen levels and the identification of prostate cancer in a large, managed care population, *British Journal of Urology*, 111(8):1245-52, 2013.
80. Chu L-H, Portugal C, Kawatkar AA, Stohl W, **Nichol MB**. Racial/Ethnic differences in the use of biologic disease-modifying antirheumatic drugs among California Medicaid rheumatoid arthritis patients, *Arthritis Care & Research*, 65(2): 299-303, 2013
79. Yen L, Wu J, Hodgkins P, Cohen RD, **Nichol MB**. Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis, *Journal of Managed Care Pharmacy*, 18(9): 701-12, 2012.
78. Wallner LP, Frencher SK, Hsu JW, Loo RK, Huang J, **Nichol MB**, Jacobsen SJ. Prostate cancer screening trends in a large, integrated care population, *Permanente Journal*, 16(3): 4-9, 2012.
77. Kawatkar AA, Hay JF, Stohl W, **Nichol MB**. Incremental expenditure of biologic diseases modifying antirheumatic treatment using instrumental variables in panel data, *Health Economics*, 22(7):807-23, 2013.
76. **Nichol MB**, An JX, Wu J, Huang J, Denham D, Frencher SK, Jacobsen SK. Cost effectiveness of a new prostate cancer detection index, *British Journal of Urology*, 110(3):353-62, 2012.
75. **Nichol MB**, Wu J, An JX, Huang J, Denham D, Frencher SK, Jacobsen SK. Budget impact analysis of a new prostate cancer risk index for prostate cancer detection, *Prostate Cancer and Prostatic Disease*, 14(3):253-61, 2011.
74. Patino-Sutton C, Varma R, Azen SP, Conti DV, **Nichol MB**, McKean-Cowdin R. "The Impact of Change in Visual Field on Health-Related Quality of Life: The Los Angeles Latino Eye Study (LALES)." *Ophthalmology*, 118(7):1310-7, 2011.
73. Yu AP, Yu YF, **Nichol MB**. Estimating the effect of medication adherence on health outcomes among patients with Type 2 diabetes – An application of marginal structural models. *Value in Health*,13(8):1038-45, 2010.
72. **Nichol MB**, Knight TK, Priest JL, Wu J, Cantrell CR. Non-adherence to clinical practice guidelines and mediations for multiple chronic conditions in a California Medicaid population. *Journal of the American Pharmacists Association*, 50(4):496-507, 2010.
71. Zeng F, An JJ, Scully R, Barrington C, Patel BV, **Nichol MB**. The impact of value-based benefit design on adherence to diabetes medications: A propensity score-weighted difference in difference evaluation. *Value in Health* 13(6):846-52, 2010.

70. Kymes SM, Plotzke MR, Li JZ, **Nichol MB**, Wu J, Fain J. The increased cost of medical services for people diagnosed with glaucoma—a decision analytic approach. *American Journal of Ophthalmology*, 150(1):74-81, 2010.
69. Benner JS, **Nichol MB**, Rovner ES, Jumadilova Z, Alvir J, Hussein M, Fanning K, Trocio JN, Brubaker L. Patient-reported reasons for discontinuing overactive bladder medication. *BJU International*, 105(9):1276-1282, 2010.
68. Chapman RH, Benner JS, Girase P, Benigno M, Axelsen K, Liu LZ, **Nichol MB**. Generic and therapeutic statin switches and disruptions in therapy. *Current Medical Research and Opinion*, 25(5):1247-1260, 2009.
67. **Nichol MB**, Knight TK, Wu J, Barron R, Penson DF. Evaluating use patterns and adherence to medications for benign prostatic hyperplasia. *Journal of Urology*, 181(5):2214-2221, 2009.
66. Gwadry-Sridhar F, Manias E, Zhang Y, Roy A, Yu-Isenberg K, Hughes D, **Nichol MB**. A framework for planning and critiquing medication compliance and persistence research using prospective study designs. *Clinical Therapeutics*, 31(2):421-435, 2009.
65. **Nichol MB**, Knight TK, Wu J, Tang SS, Cherry SB, Benner JS, Hussein M. Transition probabilities and predictors of adherence in a California Medicaid population using antihypertensive and lipid-lowering medications. *Value in Health*, 12(4):544-550, 2009.
64. Cherry SB, Benner JS, Hussein MA, Tang SSK, **Nichol MB**. The clinical and economic burden of non-adherence with antihypertensive and lipid-lowering therapy in hypertensive patients. *Value in Health*, 12(4):489-497, 2009.
63. Cella D, **Nichol MB**, Eton D, Nelson JB, Mulani P. Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy – Prostate: Results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. *Value in Health*, 12(1):124-129, 2009.
62. **Nichol MB** and Epstein JD. Separating gains and losses in health when calculating the minimum important difference in mapped utility measures. *Quality of Life Research*, 17:955-961, 2008.
61. Patel BV, Leslie RS, Thiebaud P, **Nichol MB**, Tang SSK, Solomon H, Honda D, Foody JM. Adherence with single-pill amlodipine/atorvastatin versus a two-pill regimen. *Vascular Health and Risk Management*, 4(3):673-681, 2008.
60. Yu AP, Yu Y, **Nichol MB**, Gwadry-Sridhar F. The delay of initial dispensation of statins: A potentially early indicator of medication non-persistence. *Clinical Therapeutics*, 30(4): 761-764, 2008.

59. Epstein JD, Knight TK, Epstein JB, Bride MA, **Nichol MB**. The cost of care for early and late stage oral and pharyngeal cancer in the California Medicaid population. *Head and Neck*, 30(2):178-186, 2008.
58. **Nichol MB**, Knight TK, Dow T, Borok G, Hauch O, O'Connor R. Quality of anticoagulation monitoring in nonvalvular atrial fibrillation patients: Comparison of anticoagulation clinic versus usual care. *Annals of Pharmacotherapy*, 42(1):62-70, 2008.
57. Thiebaud P, **Nichol MB**, Patel B. The demand for statins: The effect of copay change on utilization and compliance. *Health Economics*, 17(1):83-97, 2008.
56. **Nichol MB**, Knight TK, Epstein JD, Honda D, Tretiak R. Opinions regarding the Academy of Managed Care Pharmacy (AMCP) dossier submission guidelines: Results of a small survey of managed care organizations and pharmaceutical manufacturers. *Journal of Managed Care Pharmacy* 13(4):360-371, 2007.
55. **Nichol MB**. Medicare Part D and the challenge of a dynamic marketplace. *Managed Care Interface*, 19(5):17, 19 2006.
54. **Nichol MB**. The role of outcomes research in defining and measuring value in benefit decisions. *Journal of Managed Care Pharmacy*, 12(6 Suppl. B): S19-23; quiz S24-6, 2006.
53. Thiebaud P, Patel B, **Nichol MB**. Impact of rofecoxib withdrawal on Cyclooxygenase-2 utilization among patients with and without cardiovascular risk. *Value in Health* 9(6):361-368, 2006.
52. **Nichol MB**, Shi SG, Knight TK, Esquenazi A, Barron R. Risk of hip or vertebral fracture in stroke survivors using anti-spasticity medications: A case-control study. *Journal of Outcomes Research*, 10:1-11, 2006.
51. Peterson AM, Nau DP, Cramer JA, Benner JS, Gwadry-Sridhar FH, **Nichol MB**. A checklist for medication compliance and persistence studies using retrospective databases. *Value in Health*, 10(1):3-12, 2006.
50. Thiebaud P, Patel BV, **Nichol MB**, Berenbeim DM. The effect of switching on compliance and persistence: The case of statin treatment. *American Journal of Managed Care*, 11(11):670-674, 2005.
49. **Nichol MB**, Zhang L. Depression and health-related quality of life in patients with rheumatoid arthritis. *Expert Review of Pharmacoeconomics and Outcomes Research* 5(5): 645-653, 2005.
48. Yu YF, Ahn J, Yu AP, **Nichol MB**. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid program, *Value in Health* 8(4):495-505, 2005.

47. **Nichol MB**, Shi S, Knight TK, Wallace D, Weisman MH. Eligibility, utilization, and costs in a California Medicaid lupus population, *Arthritis Care and Research*, 51(6):996-1003, 2004.
46. Krapek K, King K, Warren SS, George KG, Caputo DA, Mihelich K, Holst EM, **Nichol MB**, Livengood K, Walden S, Lubowski TJ. Medication adherence and associated hemoglobin (A1C) in type 2 diabetes, *Annals of Pharmacotherapy*, 38: 1357-1362, 2004.
45. Sengupta N, **Nichol MB**, Wu J, Globe DR. Mapping the SF-12 to the HUI-3 and VAS in a managed care population, *Medical Care*, 42(9): 927-937, 2004.
44. van de Putte LBA, **Nichol MB**. Humira (adalimumab) for rheumatoid arthritis: Considerations for reimbursement by third-party payors. *Disease Management and Health Outcomes*, 12(1): 1-8, 2004.
43. Sullivan PW, Follin S, **Nichol MB**. Costs-benefit analysis of first-generation antihistamines in the treatment of allergic rhinitis. *Pharmacoeconomics*, 22(14):929-942, 2004.
42. Sullivan PW and **Nichol MB**. The economic impact of payer policies after the Rx-to-OTC switch of second-generation antihistamines, *Value in Health*, 7(4):402-412, 2004.
41. Shi CW, Asch SM, Fielder E, Gelberg L, **Nichol MB**. Consumer knowledge of over-the-counter phenazopyridine. *Annals of Family Medicine*, 2(3):240-4, 2004.
40. Sullivan PW, Follin S, **Nichol MB**. Transitioning the second-generation antihistamines to over-the-counter status: A cost-effectiveness analysis. *Medical Care*, 41(12):1382-1395, 2003.
39. Shi CW, Asch SM, Fielder E, Gelberg L, **Nichol MB**. Usage patterns of over-the-counter phenazopyridine (Pyridium). *Journal of General Internal Medicine*, 18:1-7, 2003.
38. Burk C, Gilderman A, Salas J, Berenbeim D, **Nichol MB**. The impact of an over-the-counter migraine medication program on quality of life. *Headache*, 43(3): 191-201, 2003.
37. Jones, J, Stahl D, **Nichol MB**, Azen SP. Enabling clinically based knowledge discovery in pharmacy claims data: An application in bioinformatics, *Journal of Japanese Society of Computing and Statistics (JJSCS)*, 15:39-47, 2003.
36. Marchetti A, Magar R, An P, **Nichol MB**. Clinical and economic impact of new trends in glaucoma treatment. *Medscape General Medicine*, 3(4):6, 2001.
35. **Nichol MB**, Sengupta N, Globe D. Evaluating quality adjusted life years: Estimation of the Health Utility Index (HUI) from the SF-36. *Medical Decision-Making*, 21:19-26, 2001.

34. McCombs JS, **Nichol MB**, Johnstone BM, Stimmel GL, Shi J, Smith R. Anti-psychotic drug use patterns and the cost of treating schizophrenia. *Psychiatric Services*, 51(4): 525-527, 2000.
33. Yang R, Ng S, **Nichol MB**, Laine L. A cost and performance evaluation of disposable and reusable biopsy forceps in GI endoscopy. *Gastrointestinal Endoscopy*, 51(3): 266-270, 2000.
32. Williams BR, **Nichol MB**, Lowe B, Yoon PS, McCombs JS, Nichol JM. Medication use in residential care facilities for the elderly. *Annals of Pharmacotherapy*, 33(2):149-155, 1999.
31. Venturini F, Sung JCY, **Nichol MB**, and Sellner J. Utilization patterns of antidepressant medications in a patient population served by a primary care medical group. *Journal of Managed Care Pharmacy*, 5(3):243-249, 1999.
30. Venturini F, **Nichol MB**, Sung JCY, Bailey KL, Cody M, and McCombs JS. Compliance with sulfonyleureas in a health maintenance organization: A pharmacy record-based study. *Annals of Pharmacotherapy*, 33(3): 281-288, 1999.
29. **Nichol MB**, Venturini F, Sung JCY. A critical evaluation of the methodology of the literature on medication compliance. *Annals of Pharmacotherapy*, 33(5): 531-540, 1999.
28. McCombs JS, **Nichol MB**, Stimmel GL. The role of SSRI antidepressants for treating depressed patients in the California Medicaid (Medi-Cal) program. *Value in Health*, 2(4): 269-280, 1999.
27. Liu G, Nguyen T, and **Nichol MB**. An economic analysis of antimicrobials prophylaxis against urinary tract infection in patients undergoing transurethral resection of the prostate. *Clinical Therapeutics* 21(9): 1589-1603, 1999.
26. Popovian R, Johnson KA, **Nichol MB**, and Liu G. The impact of pharmaceutical capitation to primary medical groups on the health care expenditures of Medicare HMO enrollees. *Journal of Managed Care Pharmacy*, 5(5): 414-419, 1999.
25. McCombs JS, **Nichol MB**, Johnstone BM, Stimmel GL, Shi J, Smith R. Use patterns for antipsychotic medications in Medicaid patients with schizophrenia. *J Clinical Psychiatry* 60(suppl. 19): 5-11, 1999.
24. **Nichol MB** and Harada ASM. Measuring the effects of medication use on health-related quality of life in patients with arthritis: A review. *PharmacoEconomics*, 16(5): 433-448, 1999.
23. Harada ASM and **Nichol MB**. Predicting the probability of achieving NCEP LDL-C treatment goals using HMG-CoA reductase inhibitor monotherapy. *American Journal of Managed Care*, 4(12): 1726, 1998.

22. Sung J, **Nichol MB**, Venturini F, Bailey KL, McCombs JS, and Cody M. Factors affecting patient compliance with anti-hyperlipidemic medications in a HMO population. *American Journal of Managed Care*, 4(10):1421-1432, 1998.
21. McCombs JS, Liu G, Shi J, Feng W, Cody M, Parker JP, **Nichol MB**, Hay JW, Johnson KA, Groshen SL, and Nye MT. The Kaiser Permanente/USC patient consultation study: Change in use and costs of health care services. *American Journal of Health-Systems Pharmacy*, 55(23): 2485-2499, 1998.
20. **Nichol MB**, Margolies JE, and Gill MA: Factors associated with hypertension prescribing. *Annals of Pharmacotherapy*, 31(2):154-159, 1997.
19. McCombs JS, Hou DW, Toscani MR, **Nichol MB**, and Patel NJ. The use of griseofulvin in the treatment of onychomycosis: Treatment patterns for the Medicaid population in California, *Drug Benefit Trends*, 8(2):13-34, 1996.
18. **Nichol MB**, Margolies JE, Lippa E, Rowe J, and Quell J. The application of multiple quality of life instruments in individuals with mild-to-moderate psoriasis. *PharmacoEconomics*, 10(6):644-653, 1996.
17. **Nichol MB**, Stimmel GL and Lange S: Factors predicting the use of multiple psychotropic medications. *Journal of Clinical Psychiatry*, 56(2):60-66, 1995.
16. McCombs JS and **Nichol MB**: The use of first- line and second-line outpatient antibiotics under the Saskatchewan Drug Plan. *PharmacoEconomics*, 7(6):543-554, 1995.
15. McCombs JS, Hay J, Johnson KA, Lawrence LD, **Nichol MB**, and Schneider J: Is pharmacy vision of the future too narrow? *American Journal of Health-Systems Pharmacy*, 52(11):1208-1214, 1995.
14. McCombs JS, Cody M, Besinque K, Borok G, Ershoff D, Groshen S, Hay J, Johnson KA, **Nichol MB**, and Nye MT: Measuring the impact of patient counseling in the outpatient pharmacy setting: The research design of the Kaiser-Permanente/USC Patient Consultation Study. *Clinical Therapeutics*, 17(6):1188-1206, 1995.
13. McCombs JS, **Nichol MB**, Newman C and Sclar DA: The costs of interrupting antihypertensive drug therapy in a Medicaid population. *Medical Care*, 32(3): 214-226, 1994.
12. McCombs JS and **Nichol MB**: Pharmacy-Enforced outpatient drug-treatment protocols: A case study of Medical restrictions for cefaclor. *Annals of Pharmacotherapy* 27(2):155-160, 1993.



11. McCombs JS, **Nichol MB** and Sclar DA: Single pharmacy patronage and adverse drug reactions: A case study of cimetidine. *Journal of Research in Pharmaceutical Economics*, 5(1): 3-24, 1993.
10. **Nichol MB**, McCombs JS, Boghossian T and Johnson KA: The impact of counseling on over-the-counter drug purchasing behavior. *Journal of Social and Administrative Pharmacy*, 9(1):11-20, 1992.
9. **Nichol MB** and Michael L: Critical analysis of the content and enforcement of mandatory consultation and patient profile laws. *Annals of Pharmacotherapy*, 26(9):1149-1155, 1992.
8. Zeisler JA, McCarthy JD, Richelieu WA and **Nichol MB**: Cefuroxime by continuous infusion: A new standard of care? *Infections in Medicine* 9(11):54-60, 1992.
7. **Nichol MB**, McCombs JS, Johnson KA, Spacapan S and Sclar D: The effects of consultation on over-the-counter medication purchasing decisions. *Medical Care*, 30(11):989-1003, 1992.
6. **Nichol MB**. A multidisciplinary approach to teaching pharmacy students. *American Journal of Pharmaceutical Education*, 55(4): 369-373, 1991.
5. Graddy E and **Nichol MB**: Structural reforms and licensing board performance. *American Politics Quarterly*, 18(3):376-400, 1990.
4. McCombs JS, **Nichol MB**, Stimmel G, Sclar DA, Beasley C and Gross L: The cost of antidepressant drug therapy failure: A study of antidepressant use in a Medicaid population. *Journal of Clinical Psychiatry*, 51(6:Suppl):60-69, 1990.
3. Sclar DA, McCombs JS and **Nichol MB**: Evaluating cost-effectiveness and quality of life with retrospective data: Sulfonylurea coverage under Medi-Cal. *Journal of Pharmacoepidemiology*, 1(3/4):41-60, 1990.
2. Graddy E and **Nichol MB**: Public members on occupational licensing boards: Effects on legislative regulatory reforms. *Southern Economic Journal* 55(3):610-625, 1989.
1. Jones LR and **Nichol MB**: Comprehensive reform of health care regulation: Cost control and universal access. *The Journal of Health and Human Resources Administration*, 8(3):231-248, 1986.

**OTHER ARTICLES/BOOK REVIEWS**

**Nichol MB.** Medicare Part D and the challenge of a dynamic marketplace. *Managed Care Interface*, 19(5):17, 19, 2006

**Nichol MB.** The role of outcomes research in defining and measuring value in benefit decisions. *Journal of Managed Care Pharmacy*, 6SuppB:S19-23, 2006

Setyawan J, Patel V, **Nichol MB**, Borok GM. Best practices: Evaluating modeling research at ISPOR using BMJ and ISPOR guidelines. *ISPOR Connections*, 9(5):6-9, 2003 (October 15)

Patel V, Setyawan J, Borok GM, **Nichol MB.** Evaluating retrospective study design posters presented at the ISPOR 7<sup>th</sup> Annual International Meeting. *ISPOR Connections*, 9(5):9-11, 2003 (October 15)

Mathes A, **Nichol MB**, Nightengale B, Abang A, Pham T. Measuring the health-related quality-of-life (HRQoL) of cancer patients treated with anti-emetics while undergoing bone marrow transplantation in a hospital setting, *Quality of Life Newsletter (MAPI Research Institute)*, 25:4-5, July-December 2000.

**Nichol MB**, McCombs JS, Stimmel G, and Harada ASM. Assessing the economic effectiveness of alternative treatments for schizophrenia. *The Economics of Neuroscience*, 1(2):65-70, 1999.

**Nichol MB** and Harada ASM. Special Report: Predicting the probability of achieving NCEP LDL-C treatment goals using HMG-CoA Reductase Inhibitor monotherapy. *American Journal of Managed Care*, 4(8, supp), 1998.

**Nichol MB**, Harada ASM, Venturini F, Jones J, Sherman J. Quality of life in a breast cancer population undergoing adjuvant treatment (abstract). *American Society of Clinical Oncology Proceedings*, 1999.

**Nichol MB.** Book Review: The Changing Health Care Marketplace (Zelman WA). *Inquiry*, 34(4):351-352, 1997/98.

**Nichol MB** and Gardner N. Pharmacoeconomics: The economics of psychotherapy. *Primary Psychiatry*, 5(2):21, 1998.

**Nichol MB.** Mental health applications of pharmaceutical economics. *Primary Psychiatry*, 5(2):75-78, 1998.

**Nichol MB**, McCombs JS, and Stimmel G. Assessing the economic effectiveness of alternative treatments for schizophrenia. *Primary Psychiatry*, 5(2):41-44, 1998.

Nichol MB. Pharmacoeconomics: Where we are and where we need to be. *Talbert Journal of Health Care*, 1(3):9-18, 1997

Nichol MB: A multidisciplinary approach to teaching pharmacy students. *American Journal of Pharmaceutical Education*, 55(4):369-372, 1991.

Nichol MB: Book Review: Drugs and the Elderly (Lipton HL and Lee PR). *Journal of Aging and Social Policy*, 3(1/2):233-235, 1991.

Nichol MB: Case study of organ transplantation policies in a managed care environment. *Medical Interface*, 2(9):42-43, 1989.

### INVITED CHAPTERS IN EDITED BOOKS

McCombs JS and Nichol MB: The cost of treatment failure. In: The Health Economics of Depression, Jonsson and Rosenbaum (eds.), Chichester, England: John Wiley & Sons, 1993.

Williams BR, Nichol MB, Lowe BF, McCombs JS, Yoon PS and Lipson LG: Pharmacist interventions in residential care facilities. In: Annual Review of Gerontology and Geriatrics: Volume 12, Rowe and Aronheim (eds.), New York: Springer, 1992.

Nichol MB, McCombs JS and Sclar DA: Improving medication usage by the elderly: Policy options for California. In: California Policy Choices for Long-Term Care, Liebig and Lammers (eds.), Los Angeles: Andrus Gerontology Center, Program in Policy and Service Research, 1990.

### MANUSCRIPTS IN REVIEW

Lou M, Poon JL, Riske B, Zhou ZY, Ullman M, Baker J, Koerper M, Curtis R, **Nichol MB**. Hemophilia Utilization Group Study (HUGS Vb): Characterization of baseline data

### PRESENTATIONS AND POSTERS (selected)

Niu X, Baker J, Riske B, Ullman M, Wu J, Lou M, **Nichol MB**, Clustering Health Status among Adults with Hemophilia using SF12, *International Society for Pharmacoeconomics and Outcomes Research* 18th Annual European Congress, Milan, Italy, Nov. 7-11, 2015

Chen CX, Ullman M, Hord J, Kulkarni R, Konkle BA, Baker JR, Riske B, Koerper M, Lou M, Wu J, **Nichol MB**, Characteristics Associated with Annual Bleeding Frequency Among Hemophilia Patients in the United States, *International Society for Pharmacoeconomics and Outcomes Research* 18th Annual European Congress, Milan, Italy, Nov. 7-11, 2015

- Chen CX, Konkle BA, Niu X, Baker JR, Hord J, Kulkarni R, Ullman M, Wu J, Lou M, **Nichol MB**, Associations Between Annual Bleeding Episodes and Financial Burden of Illness Among Persons with Hemophilia A and B in the United States, *National Hemophilia Foundation 67th Annual Meeting*, Dallas, TX, Aug. 13-15, 2015
- Curtis R, Riske B, Baker JR, Ullman M, Niu X, Norton K, Koerper M, Lou M, **Nichol MB**, Relative health status of young adults in the Hemophilia Utilization Group Studies (HUGS), *National Hemophilia Foundation 67th Annual Meeting*, Dallas, TX, Aug. 13-15, 2015
- Chen CX, Baker JR, Konkle BA, Ullman M, Kulkarni R, Hord J, Soni A, Wu J, Lou M, **Nichol MB**, Burden of illness among persons with Hemophilia B: direct and indirect costs, *The International Society on Thrombosis and Haemostasis 2015 Congress*, Toronto, ON, Canada, June 20-25, 2015
- Kuang B, Gassoumis ZD, Wilber KH, **Nichol MB**. Investigating the Cost of Recurrence to Adult Protective Services. *The Gerontological Society of America Annual Scientific Meeting*, Orlando, FL, November 2015.
- Navarro AE, Wyszong J, Deliema M, Schwartz E, **Nichol MB**, Wilber K. Inside the Black Box: The Case Review Process of an Elder Abuse Forensic Center. *The Gerontological Society of America Annual Scientific Meeting*, Orlando, FL, November 2015.
- Nichol MB**, Wu J, Gassoumis ZD, Yonashiro-Cho J, Wilber KH. Assess cost effectiveness of the multidisciplinary approach to elder abuse: economic evaluation of elder abuse forensic center model. The American Public Health Association Annual Meeting and Exposition, Chicago, IL, November 2015.
- Nichol MB**, Wu J, Gassoumis ZD, Yonashiro-Cho J, Wilber KH. Evaluating the Cost Effectiveness of the Elder Abuse Forensic Center Model. *The Gerontological Society of America Annual Scientific Meeting*, Washington, DC, November 2014.
- Lou M, Riske B, Wu J, Ullman M, Baker J, Koerper M, Poon JL, Niu X, Konkle B, Kulkarni R, Adkins S, Gwady-Sridhar F, Curtis R, Parish KL, **Nichol MB**, Comorbidities among adults with hemophilia: hemophilia utilization group studies (HUGS V), *National Hemophilia Foundation 66th Annual Meeting*, Washington, DC., Sep. 18-20, 2014
- Niu X, Poon JL, Kulkarni R, Lou M, Baker J, Riske B, Ullman M, Curtis RG, Wu J, Koerper M, **Nichol MB**, Association between health status and factor consumption among persons with hemophilia b using propensity score matching, *International Society for Pharmacoeconomics and Outcomes Research 19th Annual International Meeting*, Montreal, QC, Canada, May 31-June 4, 2014
- Niu X, Lou M, Poon JL, Kulkarni R, Riske B, Ullman M, Baker J, Parish K, Hord J, Curtis RG, Wu J, Koerper M, **Nichol MB**, Association between Health Status and Consumption of Factor IX Concentrate among Persons with Hemophilia B Hemophilia Utilization Group

Study - Part Vb (HUGS Vb), *World Federation of Hemophilia* 2014 World Congress, Melbourne, Australia, May 11-15, 2014

Niu X, Lou M, Baker J Poon JL, Konkle BA, Ullman M, Riske B, Hord J, Kulkarni R, Curtis RG, Koerper M, Wu J, **Nichol MB**, Measuring work or school absence associated with administration of factor concentrate in children with hemophilia in the United States – Hemophilia Utilization Group Study Part V (HUGS V), *World Federation of Hemophilia* 2014 World Congress, Melbourne, Australia, May 11-15, 2014

Baker JR, Ullman M, Riske B, Curtis RG, Koerper M, Lou M, **Nichol MB**, Embracing HUGS: The Hemophilia Utilization Group Study's Value to 21st Century Hemophilia Researchers -- Documenting Cost, Quality and Outcomes, *Thrombosis and Hemostasis Societies of North America* 2014 Annual Meeting, Chicago, IL, April 10-12, 2014

Niu X, Poon JL, Lou M, Ullman M, Koerper M, Baker J, Hord J, Konkle BA, Riske B, Buranahirun C, Gwadry-Sridhar F, Curtis RG, Kulkarni R, Soni A, **Nichol MB**, Burden of Bleeding Episodes among Persons with Hemophilia B – Hemophilia Utilization Group Study Vb (HUGS Vb), *National Hemophilia Foundation* 65th Annual Meeting, Anaheim, CA, Oct. 3-5, 2013

Poon JL, Doctor JN, Ullman MM, Riske B, Koerper M, Baker J, Gwadry-Sridhar F, Niu X, Lou M, **Nichol MB**, Longitudinal Changes in Health-Related Quality of Life for Chronic Diseases: An Example from the Hemophilia Utilization Group Study Part Va (HUGS Va), *International Society for Pharmacoeconomics and Outcomes Research* 18th Annual International Meeting, New Orleans, LA, May 18-22, 2013.

Niu X, Poon JL, Lou M, Riske B, Baker J, Ullman M, Gwadry-Sridhar F, Koerper M, **Nichol MB**, Cost To Society Due To Underemployment In Persons With Hemophilia A and B – Hemophilia Utilization Group Study V (HUGS V), *International Society for Pharmacoeconomics and Outcomes Research* 18th Annual International Meeting, New Orleans, LA, May 18-22, 2013

Niu X, Poon JL, Riske B, Baker J, Lou M, Kulkarni R, Hord J, Konkle BA, Ullman M, **Nichol MB**, Healthcare Services Utilization in Persons with Factor IX Deficiency (Hemophilia B) – Hemophilia Utilization Group Study Vb (HUGS Vb), *Hemostasis & Thrombosis Society* 2013 Scientific Symposium, Charlotte, NC, Apr. 11-13, 2013

Poon JL, Lou M, Ullman M, Baker J, Forsberg A, Konkle B, Riske B, Niu X, Curtis RG, Johnson KA, **Nichol MB**, Health Insurance Coverage for Persons with Hemophilia B – Hemophilia Utilization Group Study Vb (HUGS Vb), *National Hemophilia Foundation* 64th Annual Meeting, Orlando, FL, Nov. 8-10, 2012

Niu X, Poon JL, Lou M, Baker J, Ullman M, Riske B, Konkle B, Forsberg A, Curtis RG, Johnson KA, **Nichol MB**, Physical Activity and Health Outcomes in Adolescents and Adults

with Hemophilia B – Hemophilia Utilization Group Study Vb (HUGS Vb), *National Hemophilia Foundation 64th Annual Meeting*, Orlando, FL., Nov. 8-10, 2012

Wu J, **Nichol MB**. Impact of multiple medication compliance on disease burden in a California Medicaid population with comorbid type II diabetes and cardiovascular disease. *34rd Annual Meeting of the Society for Medical Decision Making (SMDM)*, Phoenix, AZ, October 2012.

**Nichol MB**, Wu J, Yen L. Discontinuation of oral 5-aminosalicylic acid therapy associated with incremental all-cause healthcare costs in active ulcerative colitis patients. *34rd Annual Meeting of the Society for Medical Decision Making (SMDM)*, Phoenix, AZ, October 2012.

Yen L, Wu J, **Nichol MB**. Association of non-adherence with oral 5-aminosalicylic acid therapy and disease burden in patients with ulcerative colitis. *Academy of Managed Care Pharmacy (AMCP) 2012 Educational Conference*, Cincinnati, OH, October 2012.

Yen L, Wu J, Hodgkins P, **Nichol MB**. Comparing oral 5-aminosalicylic acid treatment persistence and adherence in patients with ulcerative colitis in the United States. *5th Asia-Pacific Conference of International Society for Pharmacoeconomics and Outcomes Research*, Taipei, Taiwan, September 2012. (Best Poster finalist)

Yen L, Wu J, Hodgkins P, **Nichol MB**. Identifying risk factors associated with nonadherence to medication in patients with ulcerative colitis. *24th Annual Meeting & Expo of Academy of Managed Care Pharmacy*, San Francisco, CA, April 2012

Yen L, Wu J, Kodgkins P, **Nichol MB**. Predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis. *17th Annual International Meeting of International Society for Pharmacoeconomics and Outcomes Research, Value in Health*, Washington, DC, May 2012.

**Nichol MB**, Wu J, An JJ, Huang JT, Frencher SK, Jacobsen SK. Budget impact of a prostate cancer detection index *16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Value in Health*, Baltimore May 2011

**Nichol MB**, Wu J, An JJ, Huang JT, Denham D, Frencher SK, Jacobsen SK. Cost-effectiveness analysis of a new index for prostate cancer detection index *16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Value in Health*, Baltimore May 2011 (Best Poster finalist)

An JJ and **Nichol MB**. Impact of multiple medication compliance on cardiovascular outcomes in patients with type II diabetes and comorbid hypertension controlling for endogeneity bias, *16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Value in Health*, Baltimore May 2011

Chang JY and **Nichol MB**,. The risk of cardiovascular events associated with dietary calcium and vitamin D supplements in patients with osteoporosis, *16th Annual International Meeting*

*of the International Society for Pharmacoeconomics and Outcomes Research, Value in Health, Baltimore May 2011*

**Nichol MB, Wu J, Harker JD, Knight TK, Wong AL,.** Racial disparities in utilization of biologic and disease-modifying anti-rheumatic drugs in a California Medicaid population with rheumatoid arthritis, *16<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Value in Health, Baltimore May 2011*

Chung JK and **Nichol MB.** Health care utilization and patient financial burden analysis of pre-versus post-diagnosis of fibromyalgia syndrome, *16<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Value in Health, Baltimore May 2011*

**Nichol MB.** Health reform and the impact on recent medical graduates. *Southland Conference, Los Angeles, February 6, 2011*

Wu J, Knight TK, Priest J, Cantrell C, **Nichol MB.** The impact of depression on medication adherence in a California Medicaid population with cardiovascular disease. *32<sup>nd</sup> Annual Meeting of the Society of Medical Decision Making.*

Wu J, Knight TK, Priest J, Cantrell C, **Nichol MB,.** Finite mixture modeling analyses of health care utilization in patients with Type II diabetes and comorbid cardiovascular disease. *32<sup>nd</sup> Annual Meeting of the Society of Medical Decision Making.*

An JJ, Wu J, Huang JT, **Nichol MB.** A systematic review of the cost-effectiveness of prostate-specific antigen (PSA) in prostate cancer screening. *15<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Value in Health,*

**Nichol MB, Wu J, An JJ, Huang JT, Frencher SK, Jacobsen SK.** Budget impact analysis of a new prostate-specific antigen assay and index for prostate cancer detection. *15<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Value in Health,*

**Nichol MB, Wu J, An JJ, Knight TK, Priest J, Cantrell C.** Impact of multiple medication compliance on healthcare utilization in patients with Type II diabetes and cardiovascular disease. *15<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Value in Health,*

**Nichol MB, Wu J, An JJ, Knight TK, Priest J, Cantrell C.** Identifying risk factors associated with disease burden in patients with Type II diabetes and cardiovascular disease. *15<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Value in Health,*

Wu J, **Nichol MB, An JJ, Knight TK, Priest J, Cantrell C.** Impact of multiple cardiovascular diseases on antidiabetic medication adherence in a California Medicaid population with

comorbid Type II diabetes and cardiovascular disease. *15<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Value in Health,*

Kawatkar AA, **Nichol MB**. Disparities in disease modifying anti-rheumatoid treatment in rheumatoid arthritis. *15<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Value in Health,*

Chung JK, Knight TK, **Nichol MB**. Temporal changes in surgical procedures for management of diverticular disease. *15<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Value in Health,*

Chung JK, Knight TK, **Nichol MB**. Patient financial burden, surgical costs and reimbursements for open and laparoscopic colectomy procedures in diverticular disease. *15<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Value in Health,*

**Nichol MB**, An JJ, Wu J, Priest J, Knight TK, Cantrell C. Impact of multiple medication compliance on health care utilization in patients with comorbid Type II diabetes and cardiovascular disease. *15<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Value in Health,*

Kawatkar AA, **Nichol MB**. Expenditure of disease modifying anti-rheumatoid treatment: Lagged treatments as instrumental variables in panel data. *15<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Value in Health,*

Wu J, Gu NY, **Nichol MB**. Estimating seven health-related utilities in chronic disease conditions using a U.S. nationally representative sample. *7<sup>th</sup> World Congress of the International Health Economics Association, Beijing, 2009*

Wu J, Gu NY, **Nichol MB**. Can prospect theory improve consistency of estimated health utilities? *7<sup>th</sup> World Congress of the International Health Economics Association, Beijing, 2009*

Sullivan PW, Knight TK, Kawatkar A, Ghushchyan VH, **Nichol MB**. Racial and ethnic differences in EQ-5D index scores. *7<sup>th</sup> World Congress of the International Health Economics Association, Beijing, 2009*

**Nichol MB**. Medication adherence: The path of engagement for key stakeholders. *California Association of Physician Groups Annual Healthcare Conference, San Diego, 2009 (invited)*

**Nichol MB**. Impact of patient adherence on pay for performance goals. *National Pay for Performance Summit, San Francisco, 2009 (invited)*



**Nichol MB.** Value of medicine in a low income population. *MedImpact Users Meeting*, San Diego, 2009 (invited)

An JJ, Knight TK, Wu J, **Nichol MB.** Difference-in-difference analysis in the evaluation of an inpatient intervention among patients with community acquired pneumonia, *14<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Value in Health*, 12 (3): A23, 2009

Chang JY and **Nichol MB.** The economic impact of transitioning valacyclovir to over the counter status for the treatment of genital herpes. *14<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Value in Health*, 12 (3): A103, 2009

Kawatkar AA, and **Nichol MB.** Estimation of heterogeneous average treatment effect of biologic DMARDS-panel data correlated random coefficients model with polychotomous endogenous treatment. *14<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Value in Health*, 12 (3): A22-A23, 2009

Kawatkar AA, and **Nichol MB.** Does varying selection bias correction technique matter in estimation of treatment effects in presence of multiple endogenous treatment? *14<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Value in Health*, 12 (3): A23, 2009

Kawatkar AA, and **Nichol MB.** The impact of obesity on medical expenditure and health related quality of life. *14<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Value in Health*, 12 (3): A134, 2009

Kawatkar AA, and **Nichol MB.** Estimation of causal effects of physical activity on obesity by a recursive bivariate probit model. *14<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Value in Health*, 12 (3): A131-A132, 2009

**Nichol MB,** Knight TK, Priest JL, Wu J, Cantrell CR. Nonadherence to clinical practice guidelines for multiple disease conditions in a California Medicaid population. *14<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Value in Health*, 12 (3): A10, 2009

**Nichol MB,** Knight TK, Wu J. Medication non-adherence and non-persistence in a managed care diabetes mellitus population. *14<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Value in Health*, 12 (3): A103, 2009

Chapman RH, Benner JS, Girase P, Benigno M, Axelsen KJ, Liu L, **Nichol MB.** Therapy interruptions in patients switched from branded to other generic statins. *14<sup>th</sup> Annual*

*International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Value in Health*, 12(3): A161, 2009

**Nichol MB**, Knight TK, Wu J. The impact of demographics and insurance on quality of care in patients with major depressive disorder in a California Medicaid program. *14<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Value in Health*, 12(3): A185, 2009

**Nichol MB**, Wu J, Gu NY. Comparison between the EQ-5D and the seven derived health utilities in stroke patients using a national representative sample in the United States. *14<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Value in Health*, 12 (3): A17, 2009

Kawatkar AA and **Nichol MB**. Incremental expenditure of chronic diseases- The impact of alternative econometric models. *American Society of Health Economists*, Durham, NC, 2008

Kawatkar AA and **Nichol MB**. Evaluation of horizontal and vertical equity concerns in healthcare utilization by the US population. *American Society of Health Economists*, Durham, NC, 2008

Kawatkar AA and **Nichol MB**. Treatment effect of private insurance on resource utilization- comparing instrumental variables and maximum likelihood techniques to control selection bias. *Academy Health*, Washington, DC, 2008

**Nichol MB**, Wu J, Knight TK, Mahoney J, Berman C. Comparative effectiveness of decision tree versus logistic regression models in predicting high healthcare cost. *Society for Medical Decision Making*, Philadelphia, PA, 2008

**Nichol MB**, Wu J, Knight TK, Mahoney J, Berman C. Identifying significant predictors of high healthcare costs in diabetes using a decision tree approach. *Society for Medical Decision Making*, Philadelphia, PA, 2008

**Nichol MB**, Knight TK, Wu J, Priest JL, Cantrell CR. Association of noncompliance with diabetes care guidelines and disease burden in a California Medicaid diabetes mellitus population, *13<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Value in Health*, 11(3): A21, 2008

Wu J, **Nichol MB**, Knight TK, Mahoney J, Berman C. The impact of copayments or brand named drug on medication persistence, *13<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Value in Health*, 11(3): A30, 2008

Kawatkar A and **Nichol MB**. Analyzing inequity in health care utilization by the U.S. population, *13<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Value in Health*, 11(3):A40-A41, 2008

- Kawatkar A and **Nichol MB**. Total direct medical expenditure of chronic diseases under different econometric models, *13<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Value in Health*, 11 (3): A117, 2008
- Ahn, J, Gwadry-Sridhar F, **Nichol MB**. Temporal analysis to understand determinants of compliance, readmission to hospital and death in heart failure patients, *29<sup>th</sup> Annual Meeting of the Society for Medical Decision Making*, Pittsburgh PA, 2007
- Kawatkar A and **Nichol MB**. Determinants of insurance coverage and resource utilization by the uninsured, *29<sup>th</sup> Annual Meeting of the Society for Medical Decision Making*, Pittsburgh PA, 2007
- Nichol MB**, Knight TK, Wu J, Tang SSK, Cherry SB, Benner JS. Transition probabilities for combination use of antihypertensive and lipid-lowering medications in a California Medicaid hypertensive population, *29<sup>th</sup> Annual Meeting of the Society for Medical Decision Making*, Pittsburgh PA, 2007
- Nichol MB**, Knight TK, Wu J, Parry T, Honda DH. Adverse selection of a consumer-directed health plan on patient outcomes in a large national employer's diabetes population, *29<sup>th</sup> Annual Meeting of the Society for Medical Decision Making*, Pittsburgh PA, 2007
- Nichol MB**, Knight TK, Wu J, Parry T, Honda DH. The impact of a consumer-directed health plan on patient outcomes in a large national employer's diabetes population, *29<sup>th</sup> Annual Meeting of the Society for Medical Decision Making*, Pittsburgh PA, 2007
- Sullivan PW, Ghuschchyan V, **Nichol MB**, Coons SJ and Lee L. Health Utilities Index scores for chronic conditions in the U.S., *29<sup>th</sup> Annual Meeting of the Society for Medical Decision Making*, Pittsburgh PA, 2007
- Nichol MB** and Epstein JD. Minimally important differences in mapped utility values, *International Health Economics Association*, Copenhagen, 2007
- Vo P, Hauch O, **Nichol MB**, Borok GM, Dow TC, Levinson JD. Long-term health outcomes for patients hospitalized with unstable angina and NSTEMI in the California Medicaid population: Assessment of clopidogrel therapy in ACS, *12<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Value in Health*, 10(3): A3, 2007
- Zhang L and **Nichol MB**. Medication compliance to statin therapy and its impact on disease outcomes in Type 2 diabetes, *12<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Value in Health*, 10(3): A6, 2007
- Cherry S, Benner JS, Hussein M, Tang S, **Nichol MB**. Clinical and economic burden of nonadherence to lipid-lowering and antihypertensive therapy in a hypertensive population,

*12<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Value in Health*, 10(3): A44, 2007

Wu J, **Nichol MB**, Globe D, Gwadry-Sridhar F, Ullman M, Johnson KA. Estimating utility values for self-reported joint pain and motion limitation outcomes in adult hemophilia patients—The Hemophilia Utilization Group Study V (HUGS-V), *12<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Value in Health*, 10(3): A155, 2007 (Best Poster finalist)

**Nichol MB**, Epstein JD, Dow TD. Consistency of minimally important differences for mapped utility instruments in four major patient groups, *12<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Value in Health*, 10(3): A190, 2007

Ahn J, Talley NJ, Brook RA, **Nichol MB**, McCombs J, Baran RW. Constipation in a Medicaid population: Trends in prevalence, age, gender, and costs in the 12 months after diagnosis from 1997 to 2002 using a random sample of California Medicaid (Medi-Cal) data. *Gastroenterology* (2007), Vol. 132, No. 4, Suppl 2, A-678.

Epstein JD, Dow TD. Consistency of minimally important differences for mapped utility instruments in four major patient groups, *12<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research 2007*

Ahn J, **Nichol MB**, Brook RA, McCombs J, Baran RW. Cost estimates of chronic constipation in California Medicaid (Medi-Cal) patients. *19<sup>th</sup> Spring Educational Meeting of the Academy of Managed Care Pharmacy (AMCP)*, San Diego CA, 2007

**Nichol MB**. Interventions to improve adherence: Corporate America takes the lead (invited), *American College of Cardiology*, 2007

**Nichol MB**, Patel BV, Thiebaud P, Leslie RS, Tang SSK, Solomon H, Honda D, Foody, JM. A single pill combining antihypertensive and statin therapies improves patient adherence compared with multi-drug combinations: Results from the Caduet Adherence Research Programs and Education (CARPE) – PBM Adherence Study, *GIM Annual Meeting*, 2006

Patel BV, Leslie RS, Thiebaud P, **Nichol MB**, Tang SSK, Solomon H, Honda D, Trainer JB, Foody, JM. Adherence benefits in older patients of a single pill combining amlodipine and atorvastatin compared with multi-drug calcium channel blocker and statin combinations, *American Heart Association Annual Meeting*, 2006

Cherry SB, Hussein MA, **Nichol MB**, Tang SS, Benner JS. Short-term clinical consequences of nonadherence in patients with hypertension and multiple risk factors, *American Heart Association Annual Meeting*, 2006

- Curkendall S, **Nichol MB**, Dylan M, Nordyke R, Patel V, Zagari M, Chiou CF. Trends in out-of-pocket cost burden for rheumatoid arthritis, *American College of Rheumatology 70<sup>th</sup> Annual Meeting*, 2006
- Cherry SB, Hussein MA, **Nichol MB**, Tang SS, Benner JS. Clinical burden of non-adherence in patients with hypertension and multiple risk factors, *International Society of Hypertension Annual Meeting*, 2006
- Patel BV, Tang SSK, Thiebaud P, Leslie RS, Foody, JM, Solomon H, Honda D, **Nichol MB**. A single pill combining antihypertensive and statin therapies improves patient adherence compared with multi-drug combinations in managing cardiovascular risk, *International Society of Hypertension Annual Meeting*, 2006
- Nichol MB**, Omar M, Dow T, Kahler KH, Bamford S, Marks LD, Parise C, and Darah G. Time to medication gap, discontinuation and restart behavior with oral bisphosphonates in three large US physician groups, *American Society for Bone and Mineral Research 28th Annual Meeting*, 2006
- Graddy EA, **Nichol MB**, Hovy E, Kelly AJ. State e-governance: Technology and the regulation of health professions, *American Public Health Association 134<sup>th</sup> Annual Meeting*, Boston, 2006
- Nichol MB** and Zhang L. Ethnicity and long term treatment costs in rheumatic diseases, *(invited) ACR Impact of Arthritis Conference*, 2005
- Nichol MB** Cost-effectiveness and health policy, Washington Policy Institute, *(invited) Meeting for Western States Legislators*, 2005
- Zhang L and **Nichol MB**. The impact of depression on rheumatoid arthritis patient quality of life. *Value in Health*, 8(3): 343, 2005.
- Kim JW, Livengood KB, **Nichol MB**. Evaluation of medication adherence in chronic obstructive pulmonary disease. *Value in Health*, 8(3): 240, 2005.
- Thiebaud P, **Nichol MB**, Patel B. Compliance with statin treatment: The effects of switching to another statin after treatment initiation. *Value in Health*, 8(3): 269, 2005.
- Thiebaud P, **Nichol MB**, Patel B. Predicting statin compliance in new starters with pharmacy claims. *Value in Health*, 8(3): 272, 2005.
- Thiebaud P and **Nichol MB**. The influence of drug copay change on drug utilization: The case of small-firm employees in California. *Value in Health*, 8(3): 288, 2005.
- Thiebaud P, **Nichol MB**, Patel B. The effect of insulin treatment on health care utilization in type-II diabetes. *Value in Health*, 8(3): 361, 2005.

- Vo PG, **Nichol MB**, Borok GM. An analysis of publication rates of abstracts presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) international and European conferences during years 2000 through 2003. *Value in Health*, 8(3): 291, 2005.
- Nichol MB**, Wygant G, Borok G, Hauch O, O'Connor R, Burke MK. Impact of time in range on bleeding and stroke events in a managed care population with atrial fibrillation. *Circulation*, 111(20): E352, 2005.
- Lee L, Yu A, Yu Y, **Nichol MB**. Treatment costs of Alzheimer's disease in the California Medicaid (Medi-Cal) program from 1995 to 2002. *Value in Health*, 8(3): 256, 2005.
- Lee L, Yu A, Yu Y, **Nichol MB**. Comorbidities and incidence rates of glaucoma in the California Medicaid population: A case-control study. *Value in Health*, 8(3): 367, 2005.
- Lee L, Yu A, Yu Y, **Nichol MB**. Cost of glaucoma to the California Medicaid (Medi-Cal) program between 1995 and 2002. *Value in Health*, 8(3): 369, 2005.
- Yu A, Lee L, Yu Y, **Nichol MB**. Can use of glitazones reduce the risk of Alzheimer's disease in patients with diabetes? *Value in Health*, 8(3): 353, 2005.
- Yu A, Lee L, Yu Y, **Nichol MB**. Diagnosing physicians, prescription choice and patterns for Alzheimer's disease in California Medicaid Program. *Value in Health*, 8(3): 316, 2005.
- Yu Y, Yu A, Lee L, **Nichol MB**. Outcomes of antidepressant use in patients with Alzheimer's disease in the California Medicaid Program. *Value in Health*, 8(3): 316, 2005.
- Yu Y, Yu A, Lee L, **Nichol MB**. Assessment of comorbidity and incidence rates of Alzheimer's disease in the California Medicaid (Medi-Cal) program. *Value in Health*, 8(3): 314, 2005.
- Yu AP, Yu YF, **Nichol MB**. Bridging beyond regression-artificial neural networks in mapping from SF-36 to health utility. *Value in Health*, 8(3): 384, 2005.
- Nichol MB**, Shi SG, Knight TK, Barron RL. Assessing the likelihood of fracture with oral spasticity medications: A case control study. *Value in Health*, 7(6): 708, 2004
- Nichol MB**, Shi SG, Knight TK, Popovian R, Morita R. SSRI utilization and persistence in a California Medicaid population. *Value in Health*, 7(6): 784, Suppl. S, 2004.
- Nichol MB**, Knight TK, Shi S, Wallace DJ, Weisman MH. Eligibility, utilization, and costs in a California Medicaid lupus population. *Value in Health*, 7(3): 260, 2004.

Setyawan J, Hay JW, **Nichol MB**. Cost-effectiveness of interventions to improve patient medication compliance in major depressive disorder. *Value in Health*, 7(3): 272, 2004.

**Nichol MB**, Shi S, Knight TK, Livengood KB, Ambegaonkar AJ. Medication possession ratios for patients with calcium channel blockers and /or statins. *Value in Health*, 7(3): 330, 2004.

**Nichol MB**, Shi S, Knight TK, Popovian R, Morita R. Impact of market forces on statin persistence patterns in a California Medicaid population. *Value in Health*, 7(3):334, 2004.

**Nichol MB**, Gwadry-Sridhar F, Benner JS. *Workshop* Distributional issues in compliance assessment. October 2004.

**Nichol MB**, Shi SG, Knight TK. Comparison of changes in VAS scores and SF-36 based utility estimates. *International Society of Quality of Life*, October 2004.

**Nichol MB**. Overview of disease management policies (*invited*), *California Assembly Budget Subcommittee on Health and Human Services Review of DHS Disease Management Policies and Treatment Protocols*, November 2004.

Thiebaud P, **Nichol MB**, Patel B. Combining propensity score with classification and regression tree to evaluate the effect of insulin treatment for type II diabetes. *Society for Medical Decision Making*, October 2004.

Yu AP, Yu YF, **Nichol MB**. Can we bridge further? Evidence of limited external validity of models mapping SF-36 to health utility. *Society for Medical Decision Making*, October 2004.

Yu AP, Yu YF, **Nichol MB**. Are relationships between SF-36 subscales and health utility merely linear? *Society for Medical Decision Making*, October 2004.

Yu AP, Yu YF, **Nichol MB**. Regression artifacts in linear mapping health status measure to utility: Evidence from Monte Carlo simulations. *Society for Medical Decision Making*, October 2004.

Quach C, Chen L, Patel B, Thiebaud P, **Nichol MB**, Berenbeim D. Persistence and adherence to statin therapy in a managed care setting. *Value in Health*, 7(3): 330, 2004.

**Nichol MB** (chair), Kaplan RS, McCabe C. *Issues panel*: Can we bridge too far? Issues in mapping from health status to utility. May 2004.

**Nichol MB** (chair), Sridar-Gwadry F, Nau D, Cramer J. *Workshop*: Analytic methods in compliance research. May 2004.

Klingman D, Williams SA, Benner JS, Smith TW, **Nichol MB**, O'Donnell JC. Correlates of Compliance with Dyslipidemia Treatment Recommendations among Adults in the United

States: Findings from the 1999-2000 National Health and Nutrition Examination Survey. *Circulation*, 109(20): E294, 2004.

Patel BV, **Nichol MB**, Shi SG, Livengood K, Wang S, Berenbeim DM. Initiating Therapy with Antihypertensive Medications: Medication Use and Persistence in a Managed Care Population. *Drug Information Association*, 2004.

**Nichol MB**, Shi S, Knight TK, Livengood K. Medication persistence in a Medi-Cal hypertensive population. *Society for Medical Decision Making*, October 2003.

Krapek K, King K, Warren SS, George KG, Caputo DA, Mihelich K, Holst EM, **Nichol MB**, Livengood K, Walden SC, Lubowski TJ. Multicenter Evaluation of Medication Adherence (Morisky Survey Score) and Associated Blood Glucose Control (HbA1c) in Patients with Type 2 Diabetes. *American Diabetes Association's*, June 2003.

V Strand, Weisman MH, **Nichol MB**, Knight TK, Chang K, Chartash EK. Adalimumab improves health-related quality of life in rheumatoid arthritis patients. *Annals of the Rheumatic Diseases*, 62: 356, Suppl.1, 2003.

Weisman MH, **Nichol MB**, Knight TK, Boggs RL, Chartash EK. The importance of pain and the impact of adalimumab on pain in RA patients. *Annals of the Rheumatic Disease*, 62: 351, Suppl. 1, 2003.

Shi SG, Knight TK, Livengood KB, Lubowski T, Walden S, **Nichol MB**. Relation between medication compliance and glucose control in patients with Type 2 diabetes. *Value in Health*, 6(3): 327, 2003.

Yu AP and **Nichol MB**. Patterns and risk factors for non-compliance with HMG-CoA inhibitors in a managed care population. *Value in Health*, 9(3): 177, 2003.

Yu AP and **Nichol MB**. A time-varying survival model for the association of adherence with HMG-CoA inhibitors to the risk of adverse events. *Value in Health*, 6(3): 191, 2003.

Yu AP and **Nichol MB**. Nonconformance with NCEP-ATP III recommendation on lipid/lipoprotein measurement at baseline: A risk factor for emergency or hospitalization? *Value in Health*, 6(3): 184, 2003.

Yu AP, **Nichol MB**, Globe D. Review of quality of life instruments in pediatric asthma. *Value in Health*, 6(3): 375, 2003.

Yu AP, **Nichol MB**, Globe D. Physician habit as a determinant of medication choice. *Value in Health*, 6(3): 216, 2003.

Yu YF, Yu AP, Ahn J, **Nichol MB**. Comparison of direct health-care cost, hospital utilization and medication persistence between extended release forms (ER) of tolterodine and oxybutynin in overactive bladder/urinary incontinence patients.



*Value in Health*, 6(3): 285, 2003.

Yu YF, Yu AP, Ahn J, **Nichol MB**. Analysis of comorbidity, hospital utilization and cost of overactive bladder in a California Medicaid program: A case-control study. *Value in Health*, 6(3): 287, 2003.

Wu EQ, Johnson KA, **Nichol MB**. Instrument strength and performance of a parametric latent index model in estimating average treatment effect (ATE). *Value in Health*, 6(3): 292, 2003.

Wu EQ, Johnson KA, **Nichol MB**. Assessing the cost implications of combined pharmacotherapy in the long term management of asthma. *Value in Health*, 6(3): 369, 2003.

Wu EQ, Johnson KA, **Nichol MB**. Performance of two conditional expectation methods under unobserved selection bias. *Value in Health*, 6(3): 292, 2003.

Patel VD, Setyawan J, Borok GA, **Nichol MB**. Evaluating retrospective study posters presented at the ISPOR 7<sup>th</sup> Annual Conference. *Value in Health*, 6(3): 294, 2003.

Setyawan J, Patel VD, **Nichol MB**. Best practices: Evaluating modeling research at ISPOR using BMJ and ISPOR guidelines. *Value in Health*, 6(3): 295, 2003.

**Nichol MB** and Johnson KA. The Kaiser-Permanente Pharmacist Consultation Project. *Academy of Managed Care Pharmacy*, April 2003.

Sullivan PW and **Nichol MB**. The economic impact of payer policies after the Rx-to-OTC switch of second-generation antihistamines. *HMO Research Network*, April 2003.

**Nichol MB**, Globe DR, Wu J. Comparison of seven methods of utility assessment. *International Society for Quality of Life Research*, 11(7): 641, 2002.

Globe DR, **Nichol MB**, Wu J. The comprehensive assessment of health status in a large managed care cohort. *International Society for Quality of Life Research*, 11(7): 685, 2002.

Yu A, Hay J, **Nichol MB**. Estimating average treatment effects with multiple treatment groups—and extension of propensity score methods. *Society for Medical Decision Making*, October 2002.

Shi C, Asch S, Fielder E, Gelberg L, Brook R, Leake B, Shapiro M, **Nichol MB**. Inappropriate use of over-the-counter phenazopyridine (pyridium). *International Congress of Internal Medicine*, May 2002.

**Nichol MB**. Use of graphical displays in health outcomes research. *Academy of Managed Care Pharmacy*, April 2002.

Shi C, Asch S, Fielder E, Gelberg L, Brook R, Leake B, Shapiro M, **Nichol MB**. Usage patterns of OTC pyridium: preliminary findings. *North American Primary Care Research Group*, November 2001.

Sullivan PW and **Nichol MB**. Cost-effectiveness of converting nonsedating antihistamines from prescription to over-the-counter status. *Society for Medical Decision Making*, October 2001.

Sullivan PW, **Nichol MB**, Globe D. Comparing five methods of utility assessment across different disease states. *International Society for Quality of Life Research*, November 2001.

Jones J, Stahl D, **Nichol MB**, Azen SP. Enabling clinically based knowledge discovery in pharmacy claims data: An application in bioinformatics. *International Conference on New Trends in Computational Statistics with Biomedical Applications*, September 2001.

**Nichol MB**, Benbow CH, Harada ASM. Survey of antidepressant use by physicians in a large medical group. *American Society of Health-Systems Pharmacists*, June 2001.

**Nichol MB**. Mapping health states to health utilities: ESAS research roundtable. *American Pharmaceutical Association*, March 2001.

Shi C, Asch S, Fielder E, Gelberg L, Brook R, Leake B, Shapiro M, **Nichol MB**. Usage patterns of OTC pyridium. *Bristol-Myers Squibb National Family Medicine Research Forum*, November 2000.

**Nichol MB**, Harada ASM, Jones JP, McCombs JS, Grogg A, Gilderman A, Vaccaro JV. Utilization of antipsychotic medications in the treatment of schizophrenia in a managed care population. *American College of Clinical Pharmacy*, November 2000.

Jones JP, Rowe M, **Nichol MB**. Prevention of cardiovascular disease (CVD) and the ObGyn: The need for action by the "Woman's" Doctor. *North American Menopause Society*, September 2000.

**Nichol MB**, Harada ASM, Jones JP, Gilderman A, White DJ, Berenbeim D, Ho S. Evaluation of a managed care quality improvement initiative targeting providers to improve beta-adrenergic antagonist used in secondary prevention following acute myocardial infarction. *Association for Health Services Research*, July 2000.

Shi C, Asch S, Fielder E, Gelberg L, Brook R, Leake B, Shapiro M, **Nichol MB**. Usage patterns of OTC pyridium. *Society of Teachers of Family Medicine Fellow's Work-in-Progress Poster Session*, May 2000.

Sullivan PW, Hirsch JD, **Nichol MB**, Conner C, Teratanaut R. Content analysis of pharmaco-economic advertising in specialty and primary care journals. *Value in Health*, 3(2): 161, 2000.

- Cattaneo MJ and **Nichol MB**. Cost-effectiveness of Rituximab in relapsed, refractory, low-grade non-Hodgkin's lymphoma. *Value in Health*, 3(2): 130, 2000.
- Sengupta N, **Nichol MB**, Globe D. Preference-based index from the SF-12. *Value in Health*, 3(2): 111, 2000.
- Burk C, **Nichol MB**, Wu Q, Gilderman A, Salas J. The impact of an over-the-counter migraine medication on patient quality of life. *Value in Health*, 3(2): 88, 2000.
- Nichol MB**, Harada ASM, Jones JP, McCombs JS, Grogg A, Gilderman A, Vaccaro J. Utilization of antipsychotic medications in the treatment of schizophrenia in a managed care population. *Value in Health*, 3(2): 82, 2000.
- Nichol MB**, Venturini F, Jones J, Sherman G. A comparison of global versus disease-specific quality of life measures in patients with breast cancer undergoing adjuvant treatment. *Seventh Annual Symposium of Contributed Papers in Quality of Life Evaluation (DIA)*, April 2000.
- Burk CT and **Nichol MB**. The impact of an over-the-counter migraine medication program on patient outcomes. *Academy of Managed Care Pharmacy*, April 2000.
- Cattaneo MJ and **Nichol MB**. Multi-physician care: Barriers to compliance. *Association of Health Systems Pharmacists Mid-year meeting*, December 1999.
- Nichol MB**, Harada ASM, Jones J, Borok GS, Gilderman A, Salas J. Evaluation of a therapeutic interchange program for calcium channel blockers in hypertension: *European Conference of the International Society for Pharmacoeconomics and Outcomes Research, TPP2*, November 1999.
- Nichol MB**, Venturini F, Jones J, Sherman G. Quality of life in a breast cancer population undergoing adjuvant treatment. *European Conference of the International Society for Pharmacoeconomics and Outcomes Research, CA5*, November 1999.
- Nichol MB**, Sengupta N, Globe D. Preference based algorithm from generic HRQoL instruments: Estimating the HUI (Mark II/III) from the SF-36. *International Society for Quality of Life Research*, 8(7): 641, 1999.
- Nichol MB**. Health economics: Is cost-effectiveness still the new frontier? *Rockefeller Institute Symposium on the Future of Health Care for State Legislators*, September 1999.
- Nichol MB**, Venturini F, McCombs JS, Sengupta N, Kamath T, Tannous RE. The Costs of antihypertensive drug therapy in a Medicaid. *Value in Health*, 2(3): 148, 1999.
- Sengupta N and **Nichol MB**. An empirical analysis on ambulatory care utilization: Application of a count data model. *Value in Health*, 2(3): 215, 1999.

**Nichol MB**, Harada ASM, Jones J, Venturini F, Borok G, Johnson JN, O'Connor RD, Gilderman A. Costs and practice patterns associated with treating gastroesophageal reflux disease (GERD) in a managed care population. *Value in Health*, 2(3): 200, 1999.

White TJ and **Nichol MB**. Economic outcomes of antidepressant use in a managed care organization. *Value in Health*, 2(3): 169, 1999.

**Nichol MB**, Jones J, Godolphin DA, Bernstein E. Attainment of lipid goals in patients treated with HMG-CoA reductase inhibitors: A retrospective study. *Value in Health*, 2(3): 166, 1999

Sengupta N and **Nichol MB**. A time series and panel data approach to cross-translate descriptive health status to health preference in patients with chronic diseases. *Value in Health*, 2(3): 156, 1999.

Shi L and **Nichol MB**. The role of alternative antihyperlipidemic drugs: Patient compliance, health care utilization, and healthcare costs. *Value in Health*, 2(3): 149, 1999.

Sengupta N, **Nichol MB**, Cattaneo M. Discrete choice modeling on patient perceived compliance: Analysis of patient's health belief perspective. *Value in Health*, 2(3): 148, 1999.

McCombs JS, **Nichol MB**, Lyu RR, Shi L. The cost of treating Parkinson's Disease (PD) in the California Medicaid (Medi-Cal) program. *Value in Health*, 2(3): 142, 1999.

**Nichol MB**, Harada ASM, Jones J, Gilderman A, Salas J. Evaluation of a managed care therapeutic interchange program for calcium channel blockers in hypertension: Amlodipine to felodipine. *American Pharmaceutical Association*, March 1999.

Letourneau-Wagner JE, **Nichol MB**, Sokolskiy L, Ailor B. Gender differences in warfarin thromboprophylactic treatment. *American Pharmaceutical Association*, March 1999.

Sengupta N and **Nichol MB**. Estimating Health State Utility from Secondary Database. *Society for Medical Decision-Making*, November 1998.

Sengupta N and **Nichol MB**. A retrospective approach to evaluate QALY: Estimation of Health Utility Index from the SF-36 in a managed care population. *Value in Health*, 1(1): 41, 1998.

McCombs JS and **Nichol MB**. The cost of treating schizophrenia in the California Medicaid (MEDI-CAL) program. *Value in Health*, 1(1): 79, 1998.

White TJ and **Nichol MB**. Economic outcomes of antidepressant use in a managed care organization. *Value in Health*, 1(1): 80, 1998.

Venturini F, Sung JCY, **Nichol MB**, Sellner JC. Utilization patterns of antidepressant medications in a patient population served by a primary care medical group. *Value in Health*, 1(1): 84, 1998.

**Nichol MB**, Jones J, Salas J, Gilderman A. Treating gastro-esophageal reflux disease in a managed care population. *Academy of Managed Care Pharmacy*, May 1998.

**Nichol MB**. Treating gastro-esophageal reflux disease and depression. *California Association of Health Plans*, March 1998.

**Nichol MB**. Factors predicting hypertension treatment. *Federation of International Pharmacy*, August 1996.

**Nichol MB** and Margolies JE. Quality of life in psoriatic patients. *Quality of Life, Drug Information Association*, May 1996.

**Nichol MB** and Margolies JE. Treatment patterns for gastro-esophageal reflux disorder in a Medicaid population. *American Public Health Association*, November 1995.

**Nichol MB** and Margolies JE. Gastro-esophageal reflux disorder in an elderly Medi-Cal population. *Gerontological Society of America*, November 1995.

McCombs JS, **Nichol MB**, Newman CM. Economics of non-compliance in drug therapies in elderly populations. *Gerontological Society of America*, November 1995.

Bailey KL, **Nichol MB**, Williams BR, Lamp CD. Cost-effectiveness of pharmacists' management of antihypertensive therapy in geriatric long term care patients. *American Society of Consultant Pharmacists*, October 1995.

**Nichol MB**, Lowe B, Williams BR, McCombs JS, Yoon P. Variation in RCFE drug use over time. *Gerontological Society of America*, November 1993.

**Nichol MB**, Williams BR, Lowe B, Yoon P, McCombs JS. Use of medications in residential care facilities for the elderly. *American Public Health Association*, October 1993.

**Nichol MB** and Lange SC. Factors affecting multiple psychotropic medication use. *American Public Health Association*, November 1992.

**Nichol MB**, Graddy E, Catizone C. Factors predicting occupational licensing board consumerism. *American Public Health Association*, November 1992.

Newman C, McCombs JS, **Nichol MB**. Predicting compliance with antihypertensive medications in a Medicaid population. *American Public Health Association*, November 1992.

- Nichol MB.** The effects of centralization on pharmacy board performance. *National Association of Boards of Pharmacy Executive Officers Conference*, November 1992.
- Johnson KA, **Nichol MB**, Hisserich JC, Berger J, Weissman FG. Integrating ethics and public health courses in a pharmacy school curriculum. *International Public Health Pharmacy Issues Conference*, September 1992.
- McCombs JS and **Nichol MB.** The use of antibiotics in Saskatchewan. *Association for Health Service Research*, June 1992.
- Mak MC, Gong WC, **Nichol MB.** Incidence and management of hyperlipidemia in Hispanic patients. *Western States Residency Conference*, May 1992.
- McFadden SD, Gong WC, **Nichol MB.** Utilization of pharmacists and over-the-counter medication usage by family practice patients. *Western States Residency Conference*, May 1992.
- McCombs JS and **Nichol MB.** The use of antibiotics in Saskatchewan. *American Pharmaceutical Association*, March 1992.
- McCombs JS and **Nichol MB.** Health care costs and anti-hypertensive drug therapy. *American Pharmaceutical Association*, March 1992.
- Williams B, Lowe B, **Nichol MB**, McCombs JS, Yoon P, Lipson L. Pharmacist interventions in residential care facilities. *Gerontological Society of America*, November 1991.
- Nichol MB.** A multidisciplinary approach to teaching pharmacy students. *American Association of Colleges of Pharmacy*, July 1991.
- Nichol MB.** Cost containment: Balancing health and dollars. *Labor Insurance Board*, June 1991.
- Nichol MB.** Cost containment: Balancing health and dollars. *Kaohsiung Medical Center*, June 1991.
- Nichol MB.** Cost containment: Balancing health and dollars. *Infectious Disease Society of the Republic of China*, June 1991.
- Williams B, Lowe B, Yoon P, **Nichol MB**, McCombs JS. Medication use among elderly dwelling in residential care facilities. *American Geriatrics Society*, November 1991.
- McCombs JS, Sclar DA, **Nichol MB.** The cost of non-compliance with anti-hypertensive drug therapy: A study of Medicaid patients. *American Pharmaceutical Association*, March 1991.
- Nichol MB**, McCombs JS, Sclar DA, Johnson KA. Factors affecting consumer purchasing decisions of over-the-counter medications. *American Pharmaceutical Association*,

March 1991.

**Nichol MB**, McCombs JS and Johnson KA. Over the counter drug use by the elderly. *Annual Scientific Meeting of the Gerontological Society of America*, November 1990.

McCombs JS, **Nichol MB**, Sclar DA. Drug formulary restrictions and the risk of adverse drug reactions. *American Public Health Association*, October 1990.

McCombs JS and **Nichol MB**. Cost-effectiveness and the regulation of fee-for-service medical practice. *Second World Congress on Health Economics*, September 1990.

Sclar DA, McCombs JS, **Nichol MB**. Medi-Cal approval rate and quality of care: Case study of the sulfonyleureas. *American Pharmaceutical Association*, March 1990.

Sclar DA, McCombs JS, **Nichol MB**. Influence of state Medicaid formularies and percentage of Federal poverty coverage on access to prescription benefits. *American Pharmaceutical Association*, March 1990.

Lo Es-H, Gong WC, **Nichol MB**, McCombs JS. Inter-and intra-professional evaluations of clinical pharmacy resident performance. *American Society of Hospital Pharmacists Midyear Clinical Meeting*, December 1989.

Graddy E and **Nichol MB**. Structural reforms and licensing board performance. *Association for Public Policy Analysis and Management Research Conference*, November 1989.

**Nichol MB**. Innovations in chain pharmacy practice: Longs Drug Stores OTC Counseling Project. *American Association of Colleges of Pharmacy Annual Meeting*, July 1989.

**Nichol MB**. Non-economic aspects of technology assessment. *Symposium on Technology Assessment*, March 1989.

**Nichol MB**. Effects of structural reforms on legislative and licensing board policies. *Federation of Associations of Regulatory Boards*, February 1989.

**Nichol MB**. Evaluating the effectiveness of regulatory programs. *Clearinghouse on Licensure, Enforcement, and Regulation*, September 1988.

Graddy E and **Nichol MB**. Public members on occupational licensing boards: Effects on legislative regulatory reforms. *Western Economic Association*, July 1988.

Graddy E and **Nichol MB**. Public members on occupational licensing boards: Effects on legislative regulatory reforms. *Public Choice Society and the Economic Sciences Association*, March 1988.

**ADDITIONAL SERVICE TO THE UNIVERSITY AND PROFESSION (recent)***2015*

Community and Outcomes Research Review Panel, Co-chair, CTSI, University  
Benefits Advisory Committee, Chair, University  
Retirement Plan Oversight Committee, Member, University  
Faculty Environment Committee, Member, University  
Provosts Committee on Strategic Implementation, Member, University  
Academic Affairs Committee, Price School of Public Policy  
Appointment and Promotion Committee, Price School of Public Policy  
Dissertation Committee (E. Schwartz), Chair, PMEP  
Dissertation Committee (D. Payan), Chair, Price School of Public Policy  
Qualifying Examination Committee (C. Chen), Chair, PMEP  
Qualifying Examination Committee (X. Niu), Chair, PMEP

*2014*

Community and Outcomes Research Review Panel, Co-chair, CTSI, University  
Benefits Advisory Committee, Chair, University  
Faculty Environment Committee, Member, University  
Provosts Committee on Strategic Implementation, Member, University  
Management and Organization UCAR review, Provost's representative, University  
Academic Affairs Committee, Price School of Public Policy  
Appointment and Promotion Committee, Price School of Public Policy  
Dissertation Committee (E. Schwartz), Chair, PMEP  
Dissertation Committee (D. Payan), Chair, Price School of Public Policy  
Dissertation Committee (A. Coulourides), Member, Gerontology  
Dissertation Committee (K. Garcia), Member, Gerontology  
Qualifying Examination Committee (C. Chen), Chair, PMEP  
Qualifying Examination Committee (X. Niu), Chair, PMEP  
Qualifying Examination Committee (Y. Jiang), Chair, PMEP

*2013*

Community and Outcomes Research Review Panel, Co-chair, CTSI, University  
Benefits Advisory Committee, Chair, University  
Faculty Environment Committee, Member, University  
Provosts Committee on Strategic Implementation, Member, University  
Provosts Strategic Planning Committee, Graduate Education subcommittee, University  
Retirement Advisory Committee, Member, University  
Faculty Rights and Responsibilities Committee, Co-chair, Academic Senate  
Rules, Membership, and Elections Committee, Co-chair, Academic Senate  
Academic Affairs Committee, Price School of Public Policy  
Faculty Council, Price School of Public Policy  
Dissertation Committee (E. Schwartz), Chair, PMEP  
Dissertation Committee (D. Payan), Chair, Price School of Public Policy  
Dissertation Committee (J. Poon), Member, PMEP



Dissertation Committee (Z. Gassounimis), Member, Gerontology  
Dissertation Committee (A. Coulourides), Member, Gerontology  
Dissertation Committee (M. Riparetti-Brown), Member, Gerontology  
Dissertation Committee (Z. Lu), Member, Engineering  
Dissertation Committee (F. Chaudry), Member, Preventive Medicine (Biostatistics)  
Qualifying Exam Committee (D. Payan), Chair, Price School of Public Policy

### *2012*

Reviewer, Grant Review Section, Patient Centered Outcomes and Research Institute (PCORI)  
Technical Advisory Committee, L.A. Care Health Plan, Member  
Community and Outcomes Research Review Panel, Co-chair, CTSI, University  
Benefits Advisory Committee, Chair, University  
Faculty Environment Committee, Member, University  
Provosts Committee on Strategic Implementation, Member, University  
Provosts Strategic Planning Committee, Graduate Education subcommittee, University  
Retirement Advisory Committee, Member, University  
Faculty Rights and Responsibilities Committee, Co-chair, Academic Senate  
Rules, Membership, and Elections Committee, Co-chair, Academic Senate  
Academic Affairs Committee, Price School of Public Policy  
Dissertation Committee (E. Schwartz), Chair, PMEP  
Dissertation Committee (J. Chung), Chair, PMEP  
Dissertation Committee (R. Villacorte), Chair, PMEP  
Dissertation Committee (D. Payan), Chair, Price School of Public Policy  
Dissertation Committee (J. Suh), Member, PMEP  
Dissertation Committee (J. Poon), Member, PMEP  
Dissertation Committee (Z. Gassounimis), Member, Gerontology  
Dissertation Committee (A. Coulourides), Member, Gerontology  
Dissertation Committee (M. Riparetti-Brown), Member, Gerontology  
Dissertation Committee (Z. Lu), Member, Engineering  
Dissertation Committee (F. Chaudry), Member, Preventive Medicine (Biostatistics)  
Qualifying Exam Committee (D. Payan), Chair, Price School of Public Policy

### *2011*

Reviewer, Health Systems Research Study Section, Agency for Healthcare Research and Quality (AHRQ)  
Technical Advisory Committee, L.A. Care Health Plan, Member  
Benefits Advisory Committee, University  
Faculty Environment Committee, University  
Provost's Doctoral Scholarship and Fellowship Committee, University  
Provost's Strategic Planning Committee, Graduate Education subcommittee, University  
Faculty Rights and Responsibilities Committee, co-Chair, Academic Senate  
Rules, Membership, and Elections Committee, co-Chair, Academic Senate  
Academic Affairs Committee, School of Policy, Planning and Development  
Dissertation Committee (A. Kawatkar), Chair, PMEP

Dissertation Committee (J. Epstein), Chair, PMEP  
Dissertation Committee (J. An), Chair, PMEP  
Dissertation Committee (E. Schwartz), Chair, PMEP  
Dissertation Committee (Z. Gassounimis), Member, Gerontology  
Dissertation Committee (C. Patton), Member, Preventive Medicine (Biostatistics)  
Screening Committee (Q. Le), Member, PMEP  
Masters Project Committee (J. Chang), Chair, PMEP

### 2010

Reviewer, Health Systems Research Study Section, Agency for Healthcare Research and Quality (AHRQ)  
Technical Advisory Committee, L.A. Care Health Plan, Member  
Board of International Advisors, Center for Pharmacoeconomic Research, Chinese University of Hong Kong  
Adheris Scientific Advisory Board  
Presidential Search Committee, University  
Benefits Advisory Committee, University  
Faculty Environment Committee, University  
Provost's Doctoral Scholarship and Fellowship Committee, University  
Provost's Strategic Planning Committee, Graduate Education subcommittee, University  
Academic Affairs Committee, School of Policy, Planning and Development  
Dissertation Committee (A. Kawatkar), Chair, PMEP  
Dissertation Committee (J. Epstein), Chair, PMEP  
Dissertation Committee (J. An), Chair, PMEP  
Dissertation Committee (E. Schwartz), Chair, PMEP  
Dissertation Committee (Z. Gassounimis), Member, Gerontology  
Dissertation Committee (C. Patton), Member, Preventive Medicine (Biostatistics)  
Screening Committee (Q. Le), Member, PMEP  
Masters Project Committee (J. Chang), Chair, PMEP

### 2009

Reviewer, Health Systems Research Study Section, Agency for Healthcare Research and Quality (AHRQ)  
Technical Advisory Committee, L.A. Care Health Plan, Member  
Board of International Advisors, Center for Pharmacoeconomic Research, Chinese University of Hong Kong  
Adheris Scientific Advisory Board  
Immediate Past President, USC Academic Senate  
Presidential Search Committee, University  
Academic Senate, Executive Board, University  
Board of Trustees Academic Affairs Committee, University  
Benefits Advisory Committee, University  
Faculty Environment Committee, University  
Academic Affairs Committee, School of Policy, Planning and Development  
Dissertation Committee (A. Kawatkar), Chair, PMEP

Dissertation Committee (J. Epstein), Chair, PMEP  
Dissertation Committee (T. Yan), Member, Gerontology  
Dissertation Committee (C. Patton), Member, Preventive Medicine (Biostatistics)  
Dissertation Committee (N. Gu), Member, PMEP

### 2008

Reviewer, Health Systems Research Study Section, Agency for Healthcare Research and Quality (AHRQ)  
National Quality Forum, Education and Adherence Technical Advisory Panel, National Voluntary Consensus Standards for the Reporting of Therapeutic Drug Management Quality Project  
National Quality Forum/National Committee on Quality Assurance, Workgroup on Risk Factor Clustering/Metabolic Syndrome, Member  
Technical Advisory Committee, L.A. Care Health Plan, Member  
Board of International Advisors, Center for Pharmacoeconomic Research, Chinese University of Hong Kong  
Adheris Scientific Advisory Board  
President, USC Academic Senate  
Continuing Education Advisory Board, University  
Academic Senate, Executive Board, University  
Dissertation Committee (A. Kawatkar), Chair, PMEP  
Dissertation Committee (J. Epstein), Chair, PMEP  
Dissertation Committee (T. Yan), Member, Gerontology  
Dissertation Committee (K. Livengood), Member, PMEP  
Masters Supervisor (I. Tran), PMEP  
Masters Committee member (H. Ho), PMEP

### 2007

Reviewer, Health Systems Research Study Section, Agency for Healthcare Research and Quality (AHRQ)  
National Quality Forum, Education and Adherence Technical Advisory Panel, National Voluntary Consensus Standards for the Reporting of Therapeutic Drug Management Quality Project  
National Quality Forum/National Committee on Quality Assurance, Workgroup on Risk Factor Clustering/Metabolic Syndrome, Member  
Treasurer, Pharmacy and Therapeutics Society  
Technical Advisory Committee, L.A. Care Health Plan, Member  
ISPOR Compliance SIG: Analytic Methods Working Group, Chair  
Pharmacy Quality Alliance (PQA) Adherence Working Group, Member  
Board of International Advisors, Center for Pharmacoeconomic Research, Chinese University of Hong Kong  
Adheris Scientific Advisory Board  
Academic Vice President (incoming President), USC Academic Senate  
Continuing Education Advisory Board, University  
Academic Senate, Executive Board, University

Academic Senate Handbook Committee, Chair  
Health Collaborative, Co-Convenor, University  
Dissertation Committee (L.Zhang), Chair, PMEP  
Dissertation Committee (J. Epstein), Chair, PMEP  
Masters Supervisor (I. Tran), PMEP